

American Journal of Obstetrics & Gynecology MFM

Validation of a sonographic checklist for the detection of histologic placenta accreta spectrum --Manuscript Draft--

Manuscript Number:	AJOGMFM-23-290R1
Article Type:	Original Research
Section/Category:	Maternal
Corresponding Author:	Luke Alexander Gatta, MD Duke University School of Medicine Durham, NC UNITED STATES
First Author:	Luke Alexander Gatta, MD
Order of Authors:	Luke Alexander Gatta, MD Sarah C Ellestad, MD Brita K Boyd, MD Sally L Collins, BMBCh DPhil Brett D Einerson, MD, MPH Megan L Stephenson, MD Ibrahim Hammad, MD, MSCI Megan Varvoutis, MD, MS Anne West Honart, MD, MPhil Jerome J Federspiel, MD, PhD Amanda M Craig, MD Anthony Swartz, RDMS Julia R Salinaro, MD Shakthi Unnithan, MS Jeremy M Weber, MS Alaattin Erkanli, PhD Jennifer B Gilner, MD, PhD
Manuscript Region of Origin:	UNITED STATES
Abstract:	<p>Background: To standardize research terminology and reduce unanticipated placenta accreta spectrum (PAS), the European Working Group for Abnormally Invasive Placenta (EW-AIP) developed a consensus checklist for reporting PAS suspected on antenatal ultrasound. The diagnostic accuracy of the EW-AIP checklist has not been assessed.</p> <p>Objective: To test the performance of the EW-AIP sonographic checklist in predicting histologic PAS.</p> <p>Study Design: This is a multi-site, blinded, retrospective review of transabdominal ultrasound studies performed between 26-32 weeks gestation for subjects with histologic PAS between 2016-2020. We planned a 1:1 control cohort of subjects without histologic PAS. To reduce reader bias, we matched the control cohort for known risk factors including previa, number of prior cesarean deliveries, prior dilation and curettage (D&C), in vitro fertilization (IVF), and clinical factors affecting image quality including multiple gestation, body mass index (BMI) and gestational age at the ultrasound. Nine sonologists from 5 referral centers, blinded to the histologic outcomes, interpreted the randomized ultrasound studies using the EW-AIP checklist. The primary outcome was the sensitivity and specificity of the checklist to predict PAS. Two separate sensitivity analyses were performed: 1) we excluded subjects with mild</p>

disease (i.e. only assessed subjects with histologic increta and percreta); 2) we excluded interpretations from the 2 most junior sonologists.

Results: 78 subjects were included (39 PAS, 39 matched control). Clinical risk factors and image quality markers were statistically similar between cohorts. The checklist sensitivity (95% Confidence Interval, CI) was 76.6% (63.4%-90.6%) and specificity (95% CI) was 92.0% (63.4%-99.9%), with a positive and negative likelihood ratio of 9.6 and 0.3, respectively. When we excluded subjects with mild PAS disease, the sensitivity (95% CI) increased to 84.7% (73.6%-96.4%) and specificity was unchanged at 92.0% (83.2%-99.9%). Sensitivity and specificity were unchanged when the interpretations from the 2 most junior sonologists were excluded.

Conclusion: The 2016 EW-AIP checklist for interpreting PAS has a reasonable performance in detecting and excluding histologic placenta accreta spectrum.

Validation of a sonographic checklist for the detection of histologic placenta accreta spectrum

Luke A. GATTA, MD¹; Sarah C. ELLESTAD, MD¹; Brita K. BOYD, MD¹; Sally COLLINS, BMBCh, DPhil²; Brett D. EINERSON, MD MPH³; Megan L. STEPHENSON, MD⁴; Ibrahim HAMMAD, MD, MSCI⁵; Megan S. VARVOUTIS, MD, MS⁶; Anne WEST HONART, MD, MPhil¹; Jerome J. FEDERSPIEL, MD, PhD¹; Amanda M. CRAIG, MD¹; Anthony SWARTZ, BS, RDMS¹; Julia R. SALINARO, MD¹; Shakthi UNNITHAN, MS¹; Jeremy WEBER, MS¹; Alaattin ERKANLI, PhD¹; Jennifer B. GILNER, MD, PhD¹

¹Department of Obstetrics and Gynecology, Duke University School of Medicine
201 Trent Drive, 203 Baker House, Durham, North Carolina, 27710

²Nuffield Department of Women's and Reproductive Health, University of Oxford
Level 3, Women's Centre, John Radcliffe Hospital, Oxford; United Kingdom

³Department of Obstetrics and Gynecology, University of Utah School of Medicine
30 N 1900 E, Salt Lake City, Utah, 84132

⁴ Department of Obstetrics and Gynecology, Kaiser Permanente
700 Lawrence Expressway, Santa Clara, California, 95051

⁵Department of Obstetrics and Gynecology, Intermountain Healthcare
5063 S Cottonwood Street, Murray, Utah 84107

⁶Obstetrix of Colorado
2055 N High Street, Suite 230, Denver, Colorado, 80205

Disclosure: The authors report no conflicts of interest.

Funding: This research was funded by the Charles B. Hammond Research Fund, Duke University School of Medicine, Durham, NC. The funding source is available for departmental trainees and had no role in the study design, analysis and interpretation of the data.

Presentation: This manuscript was presented as an oral at the International Society for Ultrasound in Obstetrics & Gynecology (ISUOG) World Congress on September 16-18, 2022 in London, United Kingdom.

Corresponding author: Luke A. Gatta, MD
2608 Erwin Road, Suite 220, Room 212
Durham NC 27705
Phone: 1-919-970-7962
Fax: 1-919-681-1397
Email: luke.gatta@duke.edu

Word count: 318 abstract; 2418 manuscript

Acknowledgements: The authors would like to thank Kristin E. Weaver, who handled the data transfer agreements between institutions and ensured compliance to IRB protocols at several sites.

- 1 **Manuscript title:** Validation of a sonographic checklist for the detection of histologic
2 placenta accreta spectrum.
3
- 4 **Condensation:** A sonographic checklist for reporting suspected placenta accreta spectrum
5 has a positive likelihood ratio of 9.6 to detect (and 0.3 negative likelihood
6 ratio to exclude) histologic disease.
7
- 8 **Short title:** Sonographic checklist to predict placenta accreta spectrum
9
- 10 **AJOG at a Glance:** **A. Why was this study conducted?**
11
12 An expert consensus checklist was developed in 2016 to standardize
13 sonographic reporting of suspected placenta accreta spectrum and
14 reduce the risk of unanticipated disease. However, the diagnostic
15 performance of the checklist is not known.
16
- 17 **B. What are the key findings?**
18
19 The checklist has a positive and negative likelihood ratio of 9.6 and
20 0.3, respectively, and its sensitivity and specificity improves with more
21 severe histologic disease.
22
- 23 **C. What does this study add to what is already known?**
24
25 This study provides diagnostic accuracy to support a standardized
26 sonographic checklist for use in clinical interpretation, research, and
27 training for placenta accreta spectrum.
28
- 29 **Conflict of Interest:** The authors report no conflicts of interest.
30
- 31 **Keywords:** Abnormal placentation, abnormally adherent placenta, antenatal diagnosis,
32 checklist, delivery planning, morbidly adherent placenta, multidisciplinary
33 team, placental imaging, sonographic imaging, ultrasound
34
- 35
36
37
38
39
40

41 **Abstract**

42 Background: To standardize research terminology and reduce unanticipated placenta accreta
43 spectrum (PAS), the European Working Group for Abnormally Invasive Placenta (EW-AIP)
44 developed a consensus checklist for reporting PAS suspected on antenatal ultrasound. The
45 diagnostic accuracy of the EW-AIP checklist has not been assessed.

46 Objective: To test the performance of the EW-AIP sonographic checklist in predicting histologic
47 PAS.

48 Study Design: This is a multi-site, blinded, retrospective review of transabdominal ultrasound
49 studies performed between 26-32 weeks gestation for subjects with histologic PAS between
50 2016-2020. We matched a 1:1 control cohort of subjects without histologic PAS. To reduce
51 reader bias, we matched the control cohort for known risk factors including previa, number of
52 prior cesarean deliveries, prior dilation and curettage (D&C), in vitro fertilization (IVF), and
53 clinical factors affecting image quality including multiple gestation, body mass index (BMI) and
54 gestational age at the ultrasound. Nine sonologists from 5 referral centers, blinded to the
55 histologic outcomes, interpreted the randomized ultrasound studies using the EW-AIP checklist.
56 The primary outcome was the sensitivity and specificity of the checklist to predict PAS. Two
57 separate sensitivity analyses were performed: 1) we excluded subjects with mild disease (i.e.
58 only assessed subjects with histologic increta and percreta); 2) we excluded interpretations from
59 the 2 most junior sonologists.

60 Results: 78 subjects were included (39 PAS, 39 matched control). Clinical risk factors and image
61 quality markers were statistically similar between cohorts. The checklist sensitivity (95%
62 Confidence Interval, CI) was 76.6% (63.4%-90.6%) and specificity (95% CI) was 92.0%
63 (63.4%-99.9%), with a positive and negative likelihood ratio of 9.6 and 0.3, respectively. When

64 we excluded subjects with mild PAS disease, the sensitivity (95% CI) increased to 84.7%
65 (73.6%-96.4%) and specificity was unchanged at 92.0% (83.2%-99.9%). Sensitivity and
66 specificity were unchanged when the interpretations from the 2 most junior sonologists were
67 excluded.

68 Conclusion: The 2016 EW-AIP checklist for interpreting PAS has a reasonable performance in
69 detecting and excluding histologic placenta accreta spectrum.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87 **Introduction**

88 The incidence of placenta accreta spectrum (PAS) is rising, and it is now the leading
89 indication for puerperal hysterectomy^[1]. Management typically includes a scheduled, late
90 preterm delivery by a multidisciplinary team^[2]. Unanticipated PAS deliveries put pregnant
91 patients at highest risk for blood transfusion, ICU admission, and death^[3]. Thus, antenatal
92 diagnosis is prerequisite for surgical planning to reduce maternal morbidity and
93 mortality. Despite this necessity, a recent Maternal-Fetal Medicine Unit Network study found
94 that PAS was suspected in only 53% of subjects prior to delivery^[4].

95 The mainstay for antenatal PAS diagnosis is ultrasound. However, ultrasound is operator
96 dependent, and limited by a prior lack of standardized definitions of PAS ultrasound markers.
97 Additionally, a patient's *a priori* risk for PAS, based on historical characteristics, influences
98 interpretation of ultrasound studies. Therefore, objective assessment of PAS imaging
99 characteristics is challenging for prospective research^[5].

100 Given the need to standardize PAS ultrasound markers, in 2016 the European Working
101 Group on Abnormally Invasive Placenta (EW-AIP) produced a consensus checklist for
102 ultrasound assessment of placentation^[6]. The checklist was developed by an online
103 questionnaire of 50 international experts, and a list of 11 sonographic markers was derived from
104 expert opinion. Two years later, both the International Federation of Gynecology and Obstetrics
105 (FIGO) and the Society for Maternal Fetal Medicine (SMFM) endorsed the sonographic
106 characteristics within the checklist^[7,8]. While the EW-AIP checklist is derived from and
107 endorsed by several professional societies, the clinical performance of the checklist itself has not
108 been assessed.

109 Our objective was to assess the diagnostic accuracy of the Maternal-Fetal Medicine
110 (MFM) sonologist's overall impression of PAS using the EW-AIP checklist, and to further
111 evaluate the interrater reliability and diagnostic performance for each of the characteristics.

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132 **Materials and Methods**

133 We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive)
134 ultrasound studies including subjects prospectively enrolled at a single United States referral
135 center with suspected PAS and confirmed on hysterectomy specimen between 2016 (when the
136 EW-AIP checklist was published and adopted at our institution) and 2020. We retrospectively
137 identified a 1:1 control cohort of subjects without PAS clinically or on the final pathology report
138 (incidental diagnoses on placental specimens were not included). In an effort to control for
139 expected bias influenced by clinical risk factors for PAS, we best-matched the control cohort
140 using a greedy-matching algorithm for pre-defined clinical characteristics listed in the ACOG
141 Obstetric Care Consensus^[3], including placenta previa, number of prior cesarean deliveries, prior
142 dilation and curettage (D&C), and in vitro fertilization (IVF). Additionally, we matched clinical
143 characteristics influencing image quality including body mass index (BMI) at first prenatal visit,
144 multiple gestation, and gestational age at the time of the ultrasound. Thus, the control cohort
145 was created by including subjects with imaging conducted at the same diagnostic center and
146 cesarean delivery conducted at the same labor and delivery during the same timeframe, then
147 excluded those with PAS on final pathology or on review of operative note. The last step was
148 matching the pre-defined clinical characteristics as the disease cohort.

149 Ultrasounds studies from 26-32 weeks gestation were chosen for review, as this timing
150 was the institutional standard for follow up for suspected abnormal placentation diagnosed
151 during routine anatomy scan. Regardless of the disease severity, subjects with anticipated PAS
152 were cared for by a multidisciplinary care team and, with intraoperative confirmation and the
153 patient's consent, adherent placenta was managed with cesarean hysterectomy. Of note, while
154 not all subjects with PAS may have been managed with hysterectomy at our institution, a

155 hysterectomy was required as part of the present study design as histology was the primary
156 outcome to test the sonographic checklist.

157 After the PAS and control cohorts were created, the lead author (who did not participate
158 in interpreting the ultrasound studies) selected transabdominal images of the placenta, cervix,
159 and placental cord insertion obtained during a detailed second trimester ultrasound (CPT 76811)
160 or follow up ultrasound (CPT 76816). Selected images included both still and cine clips, and
161 greyscale and color Doppler images – no dedicated image of the placenta, cervix, or cord
162 insertion was excluded, as the EW-AIP checklist did not have a prescribed number of images.
163 The ultrasound images were de-identified, randomized, and then interpreted by 9 Maternal-Fetal
164 Medicine (MFM) sonologists blinded to final histology. The blinded sonologists were aware that
165 the ultrasound series included matched controls, but were not aware of the specific ratio for
166 matching. The 9 sonologists were from 5 United States referral centers (7 MFM faculty and 2
167 MFM fellows), recruited by email after an annual professional conference, and prior familiarity
168 with the EW-AIP checklist was not required.^[9] For each ultrasound, the sonologists were
169 provided the gestational age and the matched clinical characteristics from the Obstetric Care
170 Consensus^[3], such as number of prior cesarean deliveries or prior D&Cs. To simulate a
171 workflow at an antenatal diagnostic center, 5 minutes were suggested to review each ultrasound
172 and the sonologists were permitted to move between images and cine clips as
173 necessary. Consistent with the EW-AIP checklist, the nine sonologists could choose “present”,
174 “absent”, or “unsure” for each sonographic sign, and then prompted to predict whether there was
175 a low or high probability of PAS on pathology. To preserve integrity of statistical analysis, each
176 sonologist was required to review 100% of the ultrasounds studies, or their responses were
177 discarded.

178 Baseline demographics of the PAS and control cohorts were assessed using Chi-Square
179 or ANOVA F-Test, depending on whether the demographic was binary or continuous,
180 respectively. For the primary outcome, to measure the strength of agreement between
181 sonologists' interpretation and histologic diagnosis, a dichotomous sensitivity and specificity
182 table was created using the sonologists' aggregate overall impression. Two separate sensitivity
183 analyses were performed: 1) we excluded subjects with mild disease (i.e. excluding subjects with
184 histologic accreta and only including subjects with histologic increta and percreta on
185 hysterectomy specimen); 2) we excluded interpretations from the 2 MFM fellows who were most
186 junior in experience with ultrasound interpretation. We performed these analyses to assess how
187 disease severity and sonologist experience affected the performance of the checklist.

188 For secondary outcomes, we analyzed the interrater reliability of the sonologists'
189 responses, using Kappa statistics to compute an interrater correlation coefficient (ICC) to assess
190 the agreement for each characteristic between the 9 sonologists. Additionally, to compute the
191 aggregate sonologists' responses for individual characteristics to the true histologic diagnosis of
192 PAS, we used Cohen's Kappa, which provided a numerical summary between -1 and 1, where 0
193 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1
194 indicates perfect disagreement.

195 The images were anonymized and exported from the clinical picture archiving and
196 communications system (Viewpoint 6.11, General Electric) onto an encrypted, cloud-based
197 content management platform (Box Service, 2022). The checklist for each subject was completed
198 on REDCap 12.0.2. Statistical software used was SAS 9.4 (SAS Institute, Cary, NC). The study
199 was approved by the institutional review board at each of the five participating institutions and a
200 data transfer agreement was executed to facilitate transfer of the de-identified images. The de-

201 identified images and code used for analysis are available upon request for either research or
202 education purposes.

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224 **Results**

225 Subject recruitment is demonstrated in Figure 1. In total, there were 39 subjects with
226 PAS that met inclusion criteria including: a) performance of an ultrasound between 26-32 weeks
227 gestation, b) hysterectomy performed between 2016-2020 with histology confirming PAS. After
228 pooling the PAS cohort's pre-defined risk factors, the 1:1 control cohort was identified by
229 querying 3,348 subjects who had a cesarean delivery at the same center during the same time
230 period, but without PAS suspected clinically or on final pathology. Baseline demographics
231 between the PAS and control cohorts were statistically similar, including presence of placenta
232 previa on ultrasound (64.1% vs 59.0%, $p=0.64$), median (25th, 75th percentile) number of prior
233 cesarean deliveries (2 [1, 3], for both cohorts, $p>0.99$), prior D&Cs (23.1% vs 25.6%, $p=0.79$)
234 and IVF conception (2.6% for both cohorts, $p>0.99$). Furthermore, factors influencing image
235 quality were statistically similar including BMI, multiple gestation, and gestational age of
236 ultrasound (Table 1). Of note, although study sonologists were unaware of this fact, there were
237 more images for PAS subjects than control subjects (median 23.0 [13.0, 33.0] versus 16.0 [9.0,
238 20.0], respectively, $p=0.002$).

239 Each of the 9 sonologists completed the checklist for all subjects. The median (25th, 75th
240 percentile) years of MFM experience was 5.0 (2.8, 8.0), with a range of 1-22. Seven sonologists
241 were practicing MFM faculty (6 board-certified, 1 board-eligible), and 2 were active MFM
242 fellows.

243 Primary outcomes are listed in Table 2. The sensitivity (95% Confidence Interval, CI) of
244 the EW-AIP checklist detecting histologic PAS was 76.6% (63.4%-90.6%) and specificity (95%
245 CI) was 92.0% (63.4%-99.9%), yielding a positive likelihood ratio to detect PAS of 9.6, and a
246 negative likelihood ratio to exclude PAS of 0.3. When excluding mild cases (or histologic

247 accreta (n=10), and assessing only histologic increta and percreta) the sensitivity (95% CI)
248 increased to 84.7% (73.6%-96.4%) and specificity remained the same with a narrowed CI, 92.0%
249 (83.2%-99.9%). When excluding the responses of the two MFM fellows, the sensitivity and
250 specificity were negligibly affected, 78.0% (64.8%-91.2%) and 93.0% (85.0%-99.9%),
251 respectively.

252 For secondary outcomes, the interrater classification coefficient (which reflects the
253 degree of correlation and agreement between measurements among 9 sonologists) is shown in
254 Table 3. The two characteristics with the most agreement between sonologists was abnormal
255 placental lacunae (0.4) and uterovesical hypervascularity (0.41), indicating good reliability
256 between reviewers. Bladder wall interruption (0.19) and focal exophytic mass (0.05) were noted
257 least consistently, indicating poor reliability. In the sensitivity analysis, sonologist agreement for
258 each of the 11 characteristics increased with more severe histologic disease. Additionally, when
259 excluding the responses of the most junior sonologists, there was an increase in agreement for
260 each of the 11 characteristics, even if this did not change their overall diagnostic impression.

261 Table 4 lists the performance of individual characteristic against histologic PAS, or in
262 other words, the predictive value of histologic PAS if the individual characteristic was
263 identified. Each of the characteristics had a positive association with histological PAS, with the
264 highest agreement being myometrial thinning (0.56), loss of clear zone (0.55), and placental
265 bulge (0.48). The least correlated with severe disease was the parametrial involvement, with a
266 kappa of 0.05. Similarly, the agreement between sonographic characteristic and true PAS
267 diagnosis improved with more severe disease, as well as excluding the responses from the two
268 junior sonologists.

269

270 **Discussion**

271 Principal Findings

272 Using a consensus expert opinion initially proposed in 2016 by EW-AIP and endorsed in
273 2018 by FIGO and SMFM, we assessed the clinical performance of an ultrasound checklist for
274 the histologic diagnosis of PAS. The sensitivity (95% CI) was 76.6% (63.4%-90.6%) and
275 specificity (95% CI) was 92.0% (63.4%-99.9%) in predicting PAS, yielding a positive likelihood
276 ratio to detect PAS of 9.6, and a negative likelihood ratio to exclude PAS of 0.3. The
277 performance of the checklist to predict histologic PAS improved with more severe disease
278 (increta and percreta) and maintained a strong performance when employed by less experienced
279 sonologists (MFM fellows).

280 Results in the context of what is known

281 As our understanding of the pathophysiology of PAS evolves from a model centering on
282 *placental-invasion* to a model of *uterine-dehiscence*^[10], reporting radiologic, clinical, or
283 pathologic PAS has moved away from categorical “accreta”, “increta” and “percreta”
284 terminology to a more descriptive approach. For example, in 2018 FIGO sought to standardize
285 intraoperative findings with a clinical criteria that describes pelvic involvement of
286 placentation^[11] rather than using categorical terms. Additionally, a consensus panel of clinical
287 pathologists have replaced the categorical terminology to a 10 characteristic, descriptive grading
288 system^[12]. Similarly, driven by the need to standardize sonographic PAS markers, multiple
289 professional societies have called for a systematic approach to the evaluation of the uterus and
290 placenta. EW-AIP put forth a proposed checklist in 2016, reviewing 23 manuscripts and drafting
291 a list of 11 PAS ultrasound markers (6 markers are greyscale, 4 are 2D color Doppler, and 1 is

292 3D power Doppler)^[6]. The present study now provides clinical performance outcomes for the
293 expert-consensus checklist put forward by EW-AIP.

294 Research implications

295 Studies assessing predictive value of ultrasound markers for PAS are limited by small
296 sample sizes, retrospective designs without a control cohort, and heterogenous definitions of
297 PAS. For example, the sensitivity and specificity of hypervascular uterovesical interface ranges
298 widely from 11-100% and 36-100% respectively^[13,14]. Given the broad range of predictive
299 values for each characteristic within the checklist, the EW-AIP consensus stresses that all
300 markers should be systematically assessed and unambiguously reported until further research
301 clarifies their individual utility. Therefore, the primary outcome of this study was to report the
302 performance of the “bundle” of sonographic markers in a checklist format that may be readily
303 adopted by antenatal diagnostic centers.

304 An interesting finding was that responses from the MFM fellows did not significantly
305 impact overall predictive performance, suggesting that this checklist may have an early learning
306 curve if adopted as a part of MFM training. While the independent items within the checklist
307 had more variability, the overall impression was similar to experienced clinicians. Components
308 of the checklist may be helpful for training in familiarity and recognition, but the overall
309 impression is the most clinically relevant. Checklists have emerged for the management of
310 complex conditions to standardize evidence- or consensus-based processes and promote high
311 quality and consistent care. Accordingly, SMFM has created a checklist for surgical planning for
312 anticipated and unexpected PAS^[15]. Establishing a clinically validated checklist for the
313 systematic evaluation of placenta and uterus is imperative for education, training, and research.

314 Strengths and limitations

315 There are two key, related limitations to this study. Although the study involved blinded
316 interpretations by sonologists from multiple institutions, it is retrospective in design. Therefore,
317 images were not systematically procured in a checklist manner to capture or exclude components
318 of the checklist itself. We suspect that this limitation is pertinent to the secondary outcomes,
319 assessing the individual characteristics of the checklist. We therefore recommend caution in
320 interpreting Table 4 as these may underreport the performance against the true PAS
321 diagnosis. Second, there were more images within the PAS cohort than the control cohort, likely
322 reflecting the sonographers internal assessment as they were obtaining images for interpretation
323 or requested additional focus. While the sonologists in this study were blinded to the clinical
324 outcome, a potential bias is introduced. The lead author intentionally did not control this known
325 discrepancy in advance to avoid introducing a selection bias by “cherry picking” included
326 images for blinded review (aside from removing non-placental images).

327 There are four strengths to the study. First, the use of a control cohort matched
328 comprehensively for PAS risk factors is an effort to neutralize the impact of knowing the
329 patient’s clinical history before reading the images. Mimicking real world ultrasound reading,
330 sonologists had the basic clinical information prior to reading the scan, such as number of prior
331 cesarean or IVF conception, and the clinical characteristics were comparable between the PAS
332 and control cohorts. Second, both the PAS and control cohort were selected from the same
333 referral center, therefore standardizing variables such as sonographer education, image
334 procurement, and ultrasound machines used. Additionally, to reduce the risk of recall bias,
335 images were blinded and reviewed by sonologists from four external institutions that did not
336 participate in the subjects’ clinical care and therefore had never seen the images
337 previously. Lastly, the planned sensitivity analysis assessed the impact of disease severity as

338 well as sonologist training in order to assess potential uptake of the checklist as a part of clinical
339 care or education.

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361 Conclusion

362 Our multi-site study has assessed the diagnostic accuracy of an ultrasound checklist for
363 the detection of placenta accreta spectrum, with a high likelihood ratio. The routine
364 incorporation of this checklist may contribute to decreased unanticipated PAS cases and timely
365 referral to PAS centers, as well as standardize research terminology.

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384 **References:**

- 385 1. Machado LS. Emergency peripartum hysterectomy: Incidence, indications, risk factors
386 and outcome. *N Am J Med Sci*, 2011. 3(8):358-61.
- 387 2. ACOG, Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. *Obstet Gynecol*,
388 2018. 132(6):1519-1521.
- 389 3. Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, et al. Maternal outcomes
390 in unexpected placenta accreta spectrum disorders: single-center experience with a
391 multidisciplinary team. *Am J Obstet Gynecol*, 2019. 221(4):337 e1-337e5.
- 392 4. Bailit JL, Grobeman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al for
393 Eunice Kennedy Shriver National Institute of Child Health and Human Development
394 Maternal-Fetal Medicine Units Network. Morbidly adherent placenta treatments and
395 outcomes. *Obstet Gynecol*, 2015. 125(3):683-689.
- 396 5. Bhide A, Sebire N, Abuhamad A, Acharya G, Silver RM. Morbidly adherent placenta:
397 the need for standardization. *Ultrasound Obstet Gynecol*, 2017. 49(5):559-563.
- 398 6. Alfirevic Z, Tang AW, Collins SL, Robson SC, Palacios-Jaraquemada J for the Ad Hoc
399 International AIP Expert Group. Pro forma for ultrasound reporting in suspected
400 abnormally invasive placenta (AIP): an international consensus. *Ultrasound Obstet*
401 *Gynecol*, 2016. 47(3): p. 276-8.
- 402 7. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J for the FIGO Placenta Accreta
403 Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on
404 placenta accreta spectrum disorders: Prenatal diagnosis and screening. *Int J Gynaecol*
405 *Obstet*, 2018. 140(3):274-280.
- 406 8. Shainker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, et al.
407 Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum
408 Ultrasound Marker Task Force: Consensus on definition of markers and approach to the
409 ultrasound examination in pregnancies at risk for placenta accreta spectrum. *Am J Obstet*
410 *Gynecol*, 2021. 224(1):B2-B14.
- 411 9. Duke Obstetrics & Gynecology. Validation of ISUOG consensus for reporting placenta
412 accreta spectrum. 2021 September 7. [Video]. YouTube. <https://www.scribbr.com/apa-examples/youtube/#:~:text=To%20cite%20a%20YouTube%20video%20in%20APA%20Style%2C%20you%20include,a%20link%20to%20the%20video>.
- 413
414
- 415 10. Einerson BD, Comstock J, Silver RM, Branch DW, Woodward PJ, Kennedy A. Placenta
416 Accreta Spectrum Disorder: Uterine Dehiscence, Not Placental Invasion. *Obstet Gynecol*,
417 2020. 135(5): 1104-1111.
- 418 11. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J. FIGO consensus guidelines on
419 placenta accreta spectrum disorders: Epidemiology. *Int J Gynaecol Obstet*, 2018. 140(3):
420 265-273.
- 421 12. Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E, et al.
422 Classification and reporting guidelines for the pathology diagnosis of placenta accreta
423 spectrum (PAS) disorders: recommendations from an expert panel. *Mod Pathol*, 2020.
424 33(12):2382-2396.
- 425 13. Bowman ZS, Eller AG, Kennedy AM, Richards DS, Winter TC, Woodward PJ, Silver
426 RM. Accuracy of ultrasound for the prediction of placenta accreta. *Am J Obstet Gynecol*,
427 2014. 211(2):177 e1-7.

- 428 14. Japaraj RP, Mimin TS, Mukudan K. Antenatal diagnosis of placenta previa accreta in
429 patients with previous cesarean scar. *J Obstet Gynaecol Res*, 2007. 33(4):431-7.
- 430 15. Society for Maternal-Fetal Medicine Patient and Quality Safety Committee. Preoperative
431 planning form for suspected morbidly adherent placenta. 2020.
432 <https://www.smfm.org/checklists-and-safety-bundles>.
433
434
435
436

1 **Table 1: Baseline demographics between PAS and 1:1 matched control cohort**

	PAS on hysterectomy specimen (n=39)	Control cohort without PAS (n=39)	p value
Placenta previa	25 (64.1%)	23 (59.0%)	0.64 ¹
Number of prior cesarean	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	>0.99 ²
IVF	1 (2.6%)	1 (2.6%)	>0.99 ¹
Prior D&C	9 (23.1%)	10 (25.6%)	0.79 ¹
BMI (kg/m²)	29.3 (24.5, 36.1)	28.5 (22.6, 37.6)	0.82 ²
Multiple gestation	1 (2.6%)	1 (2.6%)	>0.99 ¹
US gestational age (weeks)	28.0 (26.0, 29.0)	29.0 (26.0, 29.0)	0.93 ²
Number of images per US	23.0 (13.0, 33.0)	13.0 (9.0, 20.0)	0.002 ²
Indication for US in control cohort			
Placental reassessment		30 (76.9%)	
Fetal Indication		6 (15.4%)	
Anatomy		3 (7.7%)	
Final pathology			<0.001 ¹
No PAS	0 (0.0%)	39.0 (100.0%)	
Accreta	10 (26.3%)	0 (0.0%)	
Increta or percreta	29 (76.3%)	0 (0.0%)	
Binary variables are represented number (%) Continuous variables are median (25 th percentile, 75 th percentile)			
IVF: <i>in vitro</i> fertilization; US: ultrasound; BMI: body mass index; PAS: placenta accreta spectrum			
¹ Chi-square; ² ANOVA F-Test			

3

4

5

6

7

8 **Table 2: Primary outcome – performance of EW-AIP checklist on detection of PAS**

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Sensitivity	76.7% (63.4%-90.6%)	84.7% (73.6%-96.4%)	78.0% (64.8%-91.2%)
Specificity	92.0% (63.4%-99.9%)	92.0% (83.2%-99.9%)	93.0% (85.0%-99.9%)
Positive Likelihood Ratio	9.6	10.6	11.8
Negative Likelihood Ratio	0.3	0.2	0.2
Sensitivity and specificity above measured with 95% confidence interval			

9

10

11

12

13

14

15

16
17
18
19
20
21

Table 3: Secondary outcome – interobserver variability of individual characteristics

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Loss of clear zone	0.25	0.49	0.50
Myometrial thinning	0.29	0.53	0.58
Abnormal placental lacunae	0.40	0.54	0.57
Bladder wall interruption	0.19	0.34	0.35
Placental bulge	0.22	0.48	0.50
Focal exophytic mass	0.05*	0.12*	0.10
Uterovesical hypervascularity	0.41	0.62	0.61
Subplacental hypervascularity	0.33	0.62	0.48
Bridging vessels	0.23	0.44	0.44
Placental lacunae feeder vessels	0.30	0.43	0.40
Parametrial involvement	0.23	0.02*	0.03*
*Mixed-effects model did not converge.			
Inter-characteristic correlation (ICC) with no restrictions is 0.71 which indicates a reasonable sonologist-to-sonologist reliability. Estimates closer to this number indicate more reliable performance measures.			

22
23

24
25
26
27
28
29


Table 4: Secondary outcome – performance of individual characteristics

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Loss of clear zone	0.55	0.63	0.59
Myometrial thinning	0.56	0.64	0.61
Abnormal placental lacunae	0.44	0.52	0.45
Bladder wall interruption	0.34	0.45	0.36
Placental bulge	0.48	0.59	0.54
Focal exophytic mass	0.11	0.17	0.13
Uterovesical hypervascularity	0.44	0.49	0.45
Subplacental hypervascularity	0.33	0.38	0.34
Bridging vessels	0.35	0.41	0.35
Placental lacunae feeder vessels	0.23	0.32	0.30
Parametrial involvement	0.049	0.045	0.12

To check agreement between sonologists' individual (binary) responses (e.g., loss of clear zone) and the true case/control status we used Cohen's kappa. This provided us with a numerical summary between -1 and 1 for each sonologist, where 0 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1 indicates perfect disagreement.

30

Figure 1: Subject recruitment, disease and for matched control



STATEMENT OF AUTHORSHIP

Each author is required to submit a signed Statement of Authorship upon submission. This applies to all submission types including Editorials, Letters to the Editor, etc.

Date: 3/22/2022

Manuscript # (if available): _____

Manuscript title: Validation of a sonographic checklist on the detection of histologic placenta accreta spectrum

Corresponding author: Luke Gatta, MD

Authors may either sign the same form or submit individually

I am an author on this submission, have adhered to all editorial policies for submission as described in the Information for Authors, attest to having met all authorship criteria, and all potential conflicts of interest / financial disclosures appears on the title page of the submission.

Signatures are required - typed signatures are unacceptable.

Typed or CLEARLY Printed Name: Luke A. GATTA, MD

Signature: 

Typed or CLEARLY Printed Name: Sarah C. ELLESTAD, MD

Signature: 

Typed or CLEARLY Printed Name: Brita K. BOYD, MD

Signature: 

Typed or CLEARLY Printed Name: Sally COLLINS, BMBCh, DPhil

Signature: 

Typed or CLEARLY Printed Name: Brett D. EINERSON, MD MPH

Signature: 

Typed or CLEARLY Printed Name: Megan L. STEPHENSON, MD

Signature: 

Typed or CLEARLY Printed Name: Ibrahim HAMMAD, MD, MSCI

Signature: 

Typed or CLEARLY Printed Name: Megan S. VARVOUTIS, MD, MS

Signature: 

Typed or CLEARLY Printed Name: Anne WEST HONART, MD, MPhil

Signature:

Anne West Honart

Typed or CLEARLY Printed Name: Jerome J. FEDERSPIEL, MD, PhD

Signature:

Jerome J. Federspiel

Typed or CLEARLY Printed Name: Amanda M. CRAIG, MD

Signature:

Amanda M. Craig

Typed or CLEARLY Printed Name: Anthony SWARTZ, BS, RDMS

Signature:

A.E. Swartz

Typed or CLEARLY Printed Name: Julia R. SALINARO, MD

Signature:

Julia Salinaro

Typed or CLEARLY Printed Name: Shakthi UNNITHAN, MS

Signature:

Shakthi Unnithan

Typed or CLEARLY Printed Name: Jeremy WEBER, MS

Signature:

Jeremy Weber

Typed or CLEARLY Printed Name: Alaattin ERKANLI, PhD

Signature:

al erkanli

Typed or CLEARLY Printed Name: Jennifer B. GILNER, MD, PhD

Signature:

J.B. Gilner

1 April 2023

Vincenzo Berghella, MD
Editor-in-Chief
American Journal of Obstetrics and Gynecology – Maternal-Fetal Medicine
Online Submission

Dear Dr. Berghella and Deputy Editors,

On behalf of our co-authors, we respectfully submit our manuscript entitled “Validation of a sonographic checklist on the detection of histologic placenta accreta spectrum” for consideration for publication in *AJOG-MFM*.

The authors attest that this an original submission, it has not been previously published, nor submitted elsewhere, and that all authors have read and approve of the submission. Data from this manuscript has not previously been published nor is currently under preparation for other manuscripts that would come in conflict with the submitted data.


Data from this manuscript were presented at as an oral communication at the International Society for Ultrasound in Obstetrics & Gynecology (ISUOG) World Congress 2022 on September 16th, 2022, in London, United Kingdom.

This study was approved 9/2020 under Duke University School of Medicine IRB Pro00025434 and Duke IRB Pro00100007, with data transfer agreements signed and on file for each of the five participating institutions.

This study was funded by the Charles B. Hammond, MD fund, an internal fund directed for Ob/Gyn trainees at Duke University.

Thank you for your review and consideration of our manuscript for your journal.

Sincerely,



Luke Alexander Gatta, MD
Fellow, Class of 2023
Division of Maternal Fetal Medicine



Jennifer B. Gilner, MD, PhD
Assistant Professor
Division of Maternal Fetal Medicine

- 1 **Manuscript title:** Validation of a sonographic checklist for the detection of histologic
2 placenta accreta spectrum.
3
- 4 **Condensation:** A sonographic checklist for reporting suspected placenta accreta spectrum
5 has a positive likelihood ratio of 9.6 to detect (and 0.3 negative likelihood
6 ratio to exclude) histologic disease.
7
- 8 **Short title:** Sonographic checklist to predict placenta accreta spectrum
9
- 10 **AJOG at a Glance:** **A. Why was this study conducted?**
11
12 An expert consensus checklist was developed in 2016 to standardize
13 sonographic reporting of suspected placenta accreta spectrum and
14 reduce the risk of unanticipated disease. However, the diagnostic
15 performance of the checklist is not known.
16
- 17 **B. What are the key findings?**
18
19 The checklist has a positive and negative likelihood ratio of 9.6 and
20 0.3, respectively, and its sensitivity and specificity improves with more
21 severe histologic disease.
22
- 23 **C. What does this study add to what is already known?**
24
25 This study provides diagnostic accuracy to support a standardized
26 sonographic checklist for use in clinical interpretation, research, and
27 training for placenta accreta spectrum.
28
- 29 **Conflict of Interest:** The authors report no conflicts of interest.
30
- 31 **Keywords:** Abnormal placentation, abnormally adherent placenta, antenatal diagnosis,
32 checklist, delivery planning, morbidly adherent placenta, multidisciplinary
33 team, placental imaging, sonographic imaging, ultrasound
34
- 35
36
37
38
39
40

41 **Abstract**

42 Background: To standardize research terminology and reduce unanticipated placenta accreta
43 spectrum (PAS), the European Working Group for Abnormally Invasive Placenta (EW-AIP)
44 developed a consensus checklist for reporting PAS suspected on antenatal ultrasound. The
45 diagnostic accuracy of the EW-AIP checklist has not been assessed.

46 Objective: To test the performance of the EW-AIP sonographic checklist in predicting histologic
47 PAS.

48 Study Design: This is a multi-site, blinded, retrospective review of transabdominal ultrasound
49 studies performed between 26-32 weeks gestation for subjects with histologic PAS between
50 2016-2020. We planned a 1:1 control cohort of subjects without histologic PAS. To reduce
51 reader bias, we matched the control cohort for known risk factors including previa, number of
52 prior cesarean deliveries, prior dilation and curettage (D&C), in vitro fertilization (IVF), and
53 clinical factors affecting image quality including multiple gestation, body mass index (BMI) and
54 gestational age at the ultrasound. Nine sonologists from 5 referral centers, blinded to the
55 histologic outcomes, interpreted the randomized ultrasound studies using the EW-AIP checklist.
56 The primary outcome was the sensitivity and specificity of the checklist to predict PAS. Two
57 separate sensitivity analyses were performed: 1) we excluded subjects with mild disease (i.e.
58 only assessed subjects with histologic increta and percreta); 2) we excluded interpretations from
59 the 2 most junior sonologists.

60 Results: 78 subjects were included (39 PAS, 39 matched control). Clinical risk factors and image
61 quality markers were statistically similar between cohorts. The checklist sensitivity (95%
62 Confidence Interval, CI) was 76.6% (63.4%-90.6%) and specificity (95% CI) was 92.0%
63 (63.4%-99.9%), with a positive and negative likelihood ratio of 9.6 and 0.3, respectively. When

64 we excluded subjects with mild PAS disease, the sensitivity (95% CI) increased to 84.7%
65 (73.6%-96.4%) and specificity was unchanged at 92.0% (83.2%-99.9%). Sensitivity and
66 specificity were unchanged when the interpretations from the 2 most junior sonologists were
67 excluded.

68 Conclusion: The 2016 EW-AIP checklist for interpreting PAS has a reasonable performance in
69 detecting and excluding histologic placenta accreta spectrum.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87 **Introduction**

88 The incidence of placenta accreta spectrum (PAS) is rising, and it is now the leading
89 indication for puerperal hysterectomy^[1]. Management typically includes a scheduled, late
90 preterm delivery by a multidisciplinary team^[2]. Unanticipated PAS deliveries put pregnant
91 patients at highest risk for blood transfusion, ICU admission, and death^[3]. Thus, antenatal
92 diagnosis is prerequisite for surgical planning to reduce maternal morbidity and
93 mortality. Despite this necessity, a recent Maternal-Fetal Medicine Unit Network study found
94 that PAS was suspected in only 53% of subjects prior to delivery^[4].

95 The mainstay for antenatal PAS diagnosis is ultrasound. However, ultrasound is operator
96 dependent, and limited by a prior lack of standardized definitions of PAS ultrasound markers.
97 Additionally, a patient's *a priori* risk for PAS, based on historical characteristics, influences
98 interpretation of ultrasound studies. Therefore, objective assessment of PAS imaging
99 characteristics is challenging for prospective research^[5].

100 Given the need to standardize PAS ultrasound markers, in 2016 the European Working
101 Group on Abnormally Invasive Placenta (EW-AIP) produced a consensus checklist for
102 ultrasound assessment of placentation^[6]. The checklist was developed by an online
103 questionnaire of 50 international experts, and a list of 11 sonographic markers was derived from
104 expert opinion. Two years later, both the International Federation of Gynecology and Obstetrics
105 (FIGO) and the Society for Maternal Fetal Medicine (SMFM) endorsed the sonographic
106 characteristics within the checklist^[7,8]. While the EW-AIP checklist is derived from and
107 endorsed by several professional societies, the clinical performance of the checklist itself has not
108 been assessed.

109 Our objective was to assess the diagnostic accuracy of the Maternal-Fetal Medicine
110 (MFM) sonologist's overall impression of PAS using the EW-AIP checklist, and to further
111 evaluate the interrater reliability and diagnostic performance for each of the characteristics.

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132 **Materials and Methods**

133 We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive)
134 ultrasound studies for subjects from a single United States referral center with PAS confirmed on
135 hysterectomy specimen between 2016 (when the EW-AIP checklist was published and adopted
136 at our institution) and 2020. We identified a 1:1 control cohort of subjects without PAS
137 clinically or on final pathology, imaged antenatally at the same diagnostic center and undergoing
138 cesarean delivery at the same hospital as the PAS subjects. In an effort to control for expected
139 bias influenced by clinical risk factors for PAS, we matched the control cohort using a greedy-
140 matching algorithm for pre-defined clinical characteristics listed in the ACOG Obstetric Care
141 Consensus^[3], including placenta previa, number of prior cesarean deliveries, prior dilation and
142 curettage (D&C), and in vitro fertilization (IVF). Additionally, we matched clinical
143 characteristics influencing image quality including body mass index (BMI), multiple gestation,
144 and gestational age at the time of the ultrasound.

145 Ultrasounds studies from 26-32 weeks gestation were chosen for review, as this timing
146 was the institutional standard for follow up for suspected abnormal placentation diagnosed
147 during routine anatomy scan. Of note, while not all subjects with anticipated PAS were managed
148 with hysterectomy at our institution, a hysterectomy was required as part of the present study
149 design as histology was the primary outcome to test the sonographic checklist.

150 After the PAS and control cohorts were created, the lead author (who did not participate
151 in interpreting the ultrasound studies) selected ultrasound images and cine clips of the placenta,
152 cervix, and placental cord insertion. The ultrasounds were de-identified, randomized, and then
153 interpreted by 9 Maternal-Fetal Medicine (MFM) sonologists blinded to final histology. The
154 blinded sonologists were aware that the ultrasound series included matched controls, but were

155 not aware of the specific ratio for matching. The 9 sonologists were from 5 United States
156 referral centers (7 MFM faculty and 2 MFM fellows), recruited by email after an annual
157 professional conference^[9] For each ultrasound, the sonologists were provided the gestational age
158 and the matched clinical characteristics from the Obstetric Care Consensus^[3], such as number of
159 prior cesarean deliveries or prior D&Cs. To simulate a workflow at an antenatal diagnostic
160 center, 5 minutes were suggested to review each ultrasound and the sonologists were permitted
161 to move between images and cine clips as necessary. Consistent with the EW-AIP checklist, the
162 nine sonologists could choose “present”, “absent”, or “unsure” for each sonographic sign, and
163 then prompted to predict whether there was a low or high probability of PAS on pathology. To
164 preserve integrity of statistical analysis, each sonologist was required to review 100% of the
165 ultrasounds studies, or their responses were discarded.

166 Baseline demographics of the PAS and control cohorts were assessed using Chi-Square
167 or ANOVA F-Test, depending on whether the demographic was binary or continuous,
168 respectively. For the primary outcome, to measure the strength of agreement between
169 sonologists’ interpretation and histologic diagnosis, a dichotomous sensitivity and specificity
170 table was created using the sonologists’ aggregate overall impression. Two separate sensitivity
171 analyses were performed: 1) we excluded subjects with mild disease (i.e. excluding subjects with
172 histologic accreta and only including subjects with histologic increta and percreta on
173 hysterectomy specimen); 2) we excluded interpretations from the 2 MFM fellows who were most
174 junior in experience with ultrasound interpretation. We performed these analyses to assess how
175 disease severity and sonologist experience affected the performance of the checklist.

176 For secondary outcomes, we analyzed the interrater reliability of the sonologists’
177 responses, using Kappa statistics to compute an interrater correlation coefficient (ICC) to assess

178 the agreement for each characteristic between the 9 sonologists. Additionally, to compute the
179 aggregate sonologists' responses for individual characteristics to the true histologic diagnosis of
180 PAS, we used Cohen's Kappa, which provided a numerical summary between -1 and 1, where 0
181 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1
182 indicates perfect disagreement.

183 The images were anonymized and exported from the clinical picture archiving and
184 communications system (Viewpoint 6.11, General Electric) onto an encrypted, cloud-based
185 content management platform (Box Service, 2022). The checklist for each subject was completed
186 on REDCap 12.0.2. Statistical software used was SAS 9.4 (SAS Institute, Cary, NC). The study
187 was approved by the institutional review board at each of the five participating institutions and a
188 data transfer agreement was executed to facilitate transfer of the de-identified images. The de-
189 identified images and code used for analysis are available upon request for either research or
190 education purposes.

191

192

193

194

195

196

197

198

199

200

201 **Results**

202 Subject recruitment is demonstrated in Figure 1. In total, there were 39 subjects with
203 PAS that met inclusion criteria including: a) performance of an ultrasound between 26-32 weeks
204 gestation, b) hysterectomy performed between 2016-2020 with histology confirming PAS. After
205 pooling the PAS cohort's pre-defined risk factors, the 1:1 control cohort was identified by
206 querying 3,348 subjects who had a cesarean delivery at the same center during the same time
207 period, but without PAS suspected clinically or on final pathology. Baseline demographics
208 between the PAS and control cohorts were statistically similar, including presence of placenta
209 previa on ultrasound (64.1% vs 59.0%, $p=0.64$), median (25th, 75th percentile) number of prior
210 cesarean deliveries (2 [1, 3], for both cohorts, $p>0.99$), prior D&Cs (23.1% vs 25.6%, $p=0.79$)
211 and IVF conception (2.6% for both cohorts, $p>0.99$). Furthermore, factors influencing image
212 quality were statistically similar including BMI, multiple gestation, and gestational age of
213 ultrasound (Table 1). Of note, although study sonologists were unaware of this fact, there were
214 more images for PAS subjects than control subjects (median 23.0 [13.0, 33.0] versus 16.0 [9.0,
215 20.0], respectively, $p=0.002$).

216 Each of the 9 sonologists completed the checklist for all subjects. The median (25th, 75th
217 percentile) years of MFM experience was 5.0 (2.8, 8.0), with a range of 1-22. Seven sonologists
218 were practicing MFM faculty (6 board-certified, 1 board-eligible), and 2 were active MFM
219 fellows.

220 Primary outcomes are listed in Table 2. The sensitivity (95% Confidence Interval, CI) of
221 the EW-AIP checklist detecting histologic PAS was 76.6% (63.4%-90.6%) and specificity (95%
222 CI) was 92.0% (63.4%-99.9%), yielding a positive likelihood ratio to detect PAS of 9.6, and a
223 negative likelihood ratio to exclude PAS of 0.3. When excluding mild cases, or histologic

224 accreta (n=10), and assessing only histologic increta and percreta, the sensitivity (95% CI)
225 increased to 84.7% (73.6%-96.4%) and specificity remained the same with a narrowed CI, 92.0%
226 (83.2%-99.9%). When excluding the responses of the two MFM fellows, the sensitivity and
227 specificity were negligibly affected, 78.0% (64.8%-91.2%) and 93.0% (85.0%-99.9%),
228 respectively.

229 For secondary outcomes, the interrater classification coefficient (which reflects the
230 degree of correlation and agreement between measurements among 9 sonologists) is shown in
231 Table 3. The two characteristics with the most agreement between sonologists was abnormal
232 placental lacunae (0.4) and uterovesical hypervascularity (0.41), indicating good reliability
233 between reviewers. Bladder wall interruption (0.19) and focal exophytic mass (0.05) were noted
234 least consistently, indicating poor reliability. In the sensitivity analysis, sonologist agreement for
235 each of the 11 characteristics increased with more severe histologic disease. Additionally, when
236 excluding the responses of the most junior sonologists, there was an increase in agreement for
237 each of the 11 characteristics, even if this did not change their overall diagnostic impression.

238 Table 4 lists the performance of individual characteristic against histologic PAS, or in
239 other words, the predictive value of histologic PAS if the individual characteristic was
240 identified. Each of the characteristics had a positive association with histological PAS, with the
241 highest agreement being myometrial thinning (0.56), loss of clear zone (0.55), and bladder wall
242 interruption (0.34). The least correlated with severe disease was the parametrial involvement,
243 with a kappa of 0.05. Similarly, the agreement between sonographic characteristic and true PAS
244 diagnosis improved with more severe disease, as well as excluding the responses from the two
245 junior sonologists.

246

247 **Discussion**

248 **Principal Findings**

249 Using a consensus expert opinion initially proposed in 2016 by EW-AIP and endorsed in
250 2018 by FIGO and SMFM, we assessed the clinical performance of an ultrasound checklist for
251 the histologic diagnosis of PAS. The sensitivity (95% CI) was 76.6% (63.4%-90.6%) and
252 specificity (95% CI) was 92.0% (63.4%-99.9%) in predicting PAS, yielding a positive likelihood
253 ratio to detect PAS of 9.6, and a negative likelihood ratio to exclude PAS of 0.3. The
254 performance of the checklist to predict histologic PAS improved with more severe disease
255 (increta and percreta) and maintained a strong performance when employed by less experienced
256 sonologists (MFM fellows).

257 **Results in the context of what is known**

258 As our understanding of the pathophysiology of PAS evolves from a model centering on
259 *placental-invasion* to a model of *uterine-dehiscence*^[10], reporting radiologic, clinical, or
260 pathologic PAS has moved away from categorical “accreta”, “increta” and “percreta”
261 terminology to a more descriptive approach. For example, in 2018 FIGO sought to standardize
262 intraoperative findings with a clinical criteria that describes pelvic involvement of
263 placentation^[11] rather than using categorical terms. Additionally, a consensus panel of clinical
264 pathologists have replaced the categorical terminology to a 10 characteristic, descriptive grading
265 system^[12]. Similarly, driven by the need to standardize sonographic PAS markers, multiple
266 professional societies have called for a systematic approach to the evaluation of the uterus and
267 placenta. EW-AIP put forth a proposed checklist in 2016, reviewing 23 manuscripts and drafting
268 a list of 11 PAS ultrasound markers (6 markers are greyscale, 4 are 2D color Doppler, and 1 is

269 3D power Doppler)^[6]. The present study now provides clinical performance outcomes for the
270 expert-consensus checklist put forward by EW-AIP.

271 Research implications

272 Studies assessing predictive value of ultrasound markers for PAS are limited by small
273 sample sizes, retrospective designs without a control cohort, and heterogenous definitions of
274 PAS. For example, the sensitivity and specificity of hypervascular uterovesical interface ranges
275 widely from 11-100% and 36-100% respectively^[13,14]. Given the broad range of predictive
276 values for each characteristic within the checklist, the EW-AIP consensus stresses that all
277 markers should be systematically assessed and unambiguously reported until further research
278 clarifies their individual utility. Therefore, the primary outcome of this study was to report the
279 performance of the “bundle” of sonographic markers in a checklist format that may be readily
280 adopted by antenatal diagnostic centers.

281 An interesting finding was that responses from the MFM fellows did not significantly
282 impact overall predictive performance, suggesting that this checklist may have an early learning
283 curve if adopted as a part of MFM training. Checklists have emerged for the management of
284 complex conditions to standardize evidence- or consensus-based processes and promote high
285 quality and consistent care. Accordingly, SMFM has created a checklist for surgical planning for
286 anticipated and unexpected PAS^[15]. Establishing a clinically validated checklist for the
287 systematic evaluation of placenta and uterus is imperative for education, training, and research.

288 Strengths and limitations

289 There are two key, related limitations to this study. Although the study involved blinded
290 interpretations by sonologists from multiple institutions, it is retrospective in design. Therefore,
291 images were not systematically procured in a checklist manner to capture or exclude components

292 of the checklist itself. We suspect that this limitation is pertinent to the secondary outcomes,
293 assessing the individual characteristics of the checklist. We therefore recommend caution in
294 interpreting Table 4 as these may underreport the performance against the true PAS
295 diagnosis. Second, there were more images within the PAS cohort than the control cohort, likely
296 reflecting the sonographers internal assessment as they were obtaining images for interpretation
297 or requested additional focus. While the sonologists in this study were blinded to the clinical
298 outcome, a potential bias is introduced. The lead author intentionally did not control this known
299 discrepancy in advance to avoid introducing a selection bias by “cherry picking” images for
300 blinded review.

301 There are four strengths to the study. First, the use of a control cohort matched
302 comprehensively for PAS risk factors is an effort to neutralize the impact of knowing the
303 patient’s clinical history before reading the images. Mimicking real world ultrasound reading,
304 sonologists had the basic clinical information prior to reading the scan, such as number of prior
305 cesarean or IVF conception, and the clinical characteristics were comparable between the PAS
306 and control cohorts. Second, both the PAS and control cohort were selected from the same
307 referral center, therefore standardizing variables such as sonographer education, image
308 procurement, and ultrasound machines used. Additionally, to reduce the risk of recall bias,
309 images were blinded and reviewed by sonologists from four external institutions that did not
310 participate in the subjects’ clinical care and therefore had never seen the images
311 previously. Lastly, the planned sensitivity analysis assessed the impact of disease severity as
312 well as sonologist training in order to assess potential uptake of the checklist as a part of clinical
313 care or education.

314

315 Conclusion

316 Our multi-site study has assessed the diagnostic accuracy of an ultrasound checklist for
317 the detection of placenta accreta spectrum, with a high likelihood ratio. The routine
318 incorporation of this checklist may contribute to decreased unanticipated PAS cases and timely
319 referral to PAS centers, as well as standardize research terminology.

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338 **References:**

- 339 1. Machado LS. Emergency peripartum hysterectomy: Incidence, indications, risk factors
340 and outcome. *N Am J Med Sci*, 2011. 3(8):358-61.
- 341 2. ACOG, Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. *Obstet Gynecol*,
342 2018. 132(6):1519-1521.
- 343 3. Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, et al. Maternal outcomes
344 in unexpected placenta accreta spectrum disorders: single-center experience with a
345 multidisciplinary team. *Am J Obstet Gynecol*, 2019. 221(4):337 e1-337e5.
- 346 4. Bailit JL, Grobeman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al for
347 Eunice Kennedy Shriver National Institute of Child Health and Human Development
348 Maternal-Fetal Medicine Units Network. Morbidly adherent placenta treatments and
349 outcomes. *Obstet Gynecol*, 2015. 125(3):683-689.
- 350 5. Bhide A, Sebire N, Abuhamad A, Acharya G, Silver RM. Morbidly adherent placenta:
351 the need for standardization. *Ultrasound Obstet Gynecol*, 2017. 49(5):559-563.
- 352 6. Alfirevic Z, Tang AW, Collins SL, Robson SC, Palacios-Jaraquemada J for the Ad Hoc
353 International AIP Expert Group. Pro forma for ultrasound reporting in suspected
354 abnormally invasive placenta (AIP): an international consensus. *Ultrasound Obstet*
355 *Gynecol*, 2016. 47(3): p. 276-8.
- 356 7. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J for the FIGO Placenta Accreta
357 Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on
358 placenta accreta spectrum disorders: Prenatal diagnosis and screening. *Int J Gynaecol*
359 *Obstet*, 2018. 140(3):274-280.
- 360 8. Shainker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, et al.
361 Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum
362 Ultrasound Marker Task Force: Consensus on definition of markers and approach to the
363 ultrasound examination in pregnancies at risk for placenta accreta spectrum. *Am J Obstet*
364 *Gynecol*, 2021. 224(1):B2-B14.
- 365 9. Duke Obstetrics & Gynecology. Validation of ISUOG consensus for reporting placenta
366 accreta spectrum. 2021 September 7. [Video]. YouTube. <https://www.scribbr.com/apa-examples/youtube/#:~:text=To%20cite%20a%20YouTube%20video%20in%20APA%20Style%2C%20you%20include,a%20link%20to%20the%20video>.
- 369 10. Einerson BD, Comstock J, Silver RM, Branch DW, Woodward PJ, Kennedy A. Placenta
370 Accreta Spectrum Disorder: Uterine Dehiscence, Not Placental Invasion. *Obstet Gynecol*,
371 2020. 135(5): 1104-1111.
- 372 11. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J. FIGO consensus guidelines on
373 placenta accreta spectrum disorders: Epidemiology. *Int J Gynaecol Obstet*, 2018. 140(3):
374 265-273.
- 375 12. Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E, et al.
376 Classification and reporting guidelines for the pathology diagnosis of placenta accreta
377 spectrum (PAS) disorders: recommendations from an expert panel. *Mod Pathol*, 2020.
378 33(12):2382-2396.
- 379 13. Bowman ZS, Eller AG, Kennedy AM, Richards DS, Winter TC, Woodward PJ, Silver
380 RM. Accuracy of ultrasound for the prediction of placenta accreta. *Am J Obstet Gynecol*,
381 2014. 211(2):177 e1-7.

- 382 14. Japaraj RP, Mimin TS, Mukudan K. Antenatal diagnosis of placenta previa accreta in
383 patients with previous cesarean scar. *J Obstet Gynaecol Res*, 2007. 33(4):431-7.
- 384 15. Society for Maternal-Fetal Medicine Patient and Quality Safety Committee. Preoperative
385 planning form for suspected morbidly adherent placenta. 2020.
386 <https://www.smfm.org/checklists-and-safety-bundles>.
387
388
389
390

REVIEWER COMMENTS:

REVIEWER 1, POINT #1

- A. *The authors evaluated for the first time the diagnostic performance of the EW-AIP checklist in the detection of placenta accreta and increta. It is a checklist with different items allowing to conduct the ultrasound examination in case of suspicion of an abnormal invasive placenta and to evaluate the probability of a PAS in order to improve the management of the women.*

The authors report a good performance in the detection of placenta accreta (sensitivity 76.6% and specificity 92.0% with positive and negative likelihood ratio at 9.6 and 0.3 respectively).

Overall, the manuscript is well written and the methodology is robust. Although the total number of examinations evaluated is moderate (39 ultrasounds with confirmed PAS and 39 controls), the number of sonographers is nine, which seems correct for the evaluation of performance and inter-sonographer variability.

A few points to note, however concerning the methods:

All women included in the "confirmed accreta" group had a hysterectomy (histological diagnosis). There is no information on the management of placenta accreta at the center in question (% hysterectomy and % conservative treatment). It is possible that patients who have a hysterectomy for placenta accreta (rather than conservative treatment) have more severe placenta accreta. This checklist would therefore be evaluated and effective for severe placenta accreta and therefore may be more visible on ultrasound. This is a limitation that I think it is appropriate to mention (external validity)

- B. At the institution, cesarean hysterectomy was the default treatment for all anticipated disease. The purpose of the EW-AIP checklist (the primary exposure) was to detect clinically relevant disease that would be at highest risk for maternal morbidity.
- a. In response to the reviewer, **we clarified this in the text.**
- C. Lines 150-66
- D. "Ultrasounds studies from 26-32 weeks gestation were chosen for review, as this timing was the institutional standard for follow up for suspected abnormal placentation diagnosed during routine anatomy scan. **Regardless of the disease severity, subjects with anticipated PAS were managed by a multidisciplinary care team and, with intraoperative confirmation and the patient's consent, the disease was managed with cesarean hysterectomy. Of note, while not all subjects with PAS may have been managed with hysterectomy at our institution, a hysterectomy was required as part of the present study design as histology was the primary outcome to test the sonographic checklist.**"

REVIEWER 1, POINT #2

- A. *It is not specified whether all the women in the confirmed accreta group had an antenatal diagnosis of placenta accreta or whether there were incidental discoveries as well (with ultrasound performed in the center anyway), to be specified.*
- B. All subjects in the disease cohort had suspected PAS.

- a. Table 1 notes that 10 subjects (26.3%) had suspected accreta, and 29 (76.3%) subjects had suspected increta or percreta. No subject was incidentally diagnosed on pathology.
 - b. In response to the reviewer, **we clarified this in the text.**
- C. Lines 134-7.
- D. “We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive) ultrasound studies including subjects prospectively enrolled at a single United States referral center with **suspected PAS and confirmed on hysterectomy specimen** between 2016 (when the EW-AIP checklist was published and adopted at our institution) and 2020”

REVIEWER 1, POINT #3

- A. *The main author made the selection of the images from the ultrasound examinations, the modalities of selection of these images are not very well explained and it seems to me that this can be a major bias.*
- B. **We added detail regarding the selection of ultrasound images.** After the disease and control cohorts were selected by risk factors, the lead author selected placental, cervix, and cord insertion images included with either the detailed anatomy or follow up scans. To reduce the risk of bias, all placental images were included, and the author did not participate in interpretation.
- a. Of note, the EW-AIP checklist studied does not include a prescribed number of images to include, nor impart recommendations on ultrasound settings. This is an area for further research.¹
- C. Lines 167-72.
- D. “After the PAS and control cohorts were created, the lead author (who did not participate in interpreting the ultrasound studies) **selected transabdominal images of the placenta, cervix, and placental cord insertion obtained during a detailed second trimester ultrasound (CPT 76811) or follow up ultrasound (CPT 76816). Selected images included both still and cine clips, and greyscale and color Doppler images – no dedicated image of the placenta, cervix, or cord insertion was excluded, as the EW-AIP checklist did not have prescribed number of images”**

REVIEWER 1, POINT #4

- A. *The authors therefore use this checklist a posteriori, whereas it is a checklist intended to guide the sonographer and therefore to focus his examination on the search for these signs. Unless I am mistaken, this limit is not mentioned in the manuscript.*
- B. **Yes -- this was an anticipated limitation and mentioned in the text.** The checklist is intended for interpretation, not image procurement. Future research must guide recommendations to optimize image settings, and the manuscript supports training the sonographer to consider the checklist when obtaining images.
- C. Lines 332-39

¹ Alfrevic Z, Tang AW, Collins SL, Robson SC, Palacios-Jaraquemada J for the Ad Hoc International AIP Expert Group. Pro forma for ultrasound reporting in suspected abnormally invasive placenta (AIP): an international consensus. *Ultrasound Obstet Gynecol*, 2016. 47(3): p. 276-8.

- D. “Therefore, **images were not systematically procured in a checklist manner to capture or exclude components of the checklist itself. We suspect that this limitation is pertinent to the secondary outcomes, assessing the individual characteristics of the checklist.** We therefore recommend caution in interpreting Table 4 as these may underreport the performance against the true PAS diagnosis. Second, there were more images within the PAS cohort than the control cohort, likely reflecting the sonographers internal assessment as they were obtaining images for interpretation or requested additional focus.”

REVIEWER 2, POINT #1

- A. *The authors performed a retrospective matched case-control study to evaluate the performance characteristics of the EW-AIP checklist for predicting histologic PAS. They found the checklist performed reasonably with a 76.6% sensitivity and a 92.0% specificity. There was also moderate interobserver agreement in assessing elements of the checklist. I think the study is well-designed and reasonably written. I have the following minor suggestions:*

In order to improve clarity, change line 50 of the abstract from "We planned a 1:1 control cohort of subjects without histologic PAS" to "We matched 1:1 to a control cohort of subjects without histologic PAS".

- B. Changed as requested.
- C. Line 50
- D. We **matched** a 1:1 control cohort of subjects without histologic PAS.

REVIEWER 2, POINT #2

- A. *Regarding table 4 (Lines 238-242), the three characteristics with the highest agreement are myometrial thinning (0.56), loss of clear zone (0.55) and placental bulge (0.48); not bladder wall interruption (0.34).*
- B. Thank you! The reviewer is correct. Table 4 is correct as shown, and we edited the text to reflect the results.
- C. Lines 277-9.
- D. “Each of the characteristics had a positive association with histological PAS, with the highest agreement being myometrial thinning (0.56), loss of clear zone (0.55), and **placental bulge (0.48).**”

REVIEWER 3, POINT #1

- A. *Thank you for the opportunity to review this paper.*

This is a paper validating the EW-AIP checklist for ultrasound diagnosis of placenta accreta spectrum (PAS) disorders. Strengths include the large number of MFMs from multiple institutions reviewing ultrasounds. Consideration of individual scoring components is also a plus. The number of patients and controls is reasonable given the use of full clinical studies and the rarity of hysterectomy cases.

My largest concerns with the paper involve the controls. Some of the issues are non-modifiable given a retrospective study design and the labor-intensive nature of reviewing cases (that is - I do not recommend doing a second set of controls(!)). However, I think a more extensive description of this group would be useful. What is the indication for the exam (this might be included in a table)?

B. In response, we reviewed the indications for follow up ultrasounds for the control cohort, and **added this to the paper in Table 1**. Out of the 39 control subjects, 30 (76.9%) were indicated by placental reassessment, 6 (15.4%) were for fetal indications, 3 (7.7%) were for anatomy ultrasounds.

C. Added to Table 1

D.

Indication for US in control cohort			
Placental reassessment		30 (76.9%)	
Fetal Indication		6 (15.4%)	
Anatomy		3 (7.7%)	

REVIEWER 3, POINT #3

A. *How was it established that controls were "without PAS suspected clinically or on final pathology"? Does "clinical suspicion of PAS" refer only to pre-delivery suspicion or does it include abnormally adherent placenta at delivery*

B. The control cohort was created by querying all patients who had:

- Detailed anatomy (76811) or follow up ultrasound (76816) (same as disease)
- Between 2016-2020 at institution's Diagnostic Center (same as disease)
- Cesarean delivery at the institutions Labor & Delivery (same as disease)

And excluding those with:

- Placenta accreta on final pathology reports (unlike disease)
- Placenta accreta noted on the operative note (unlike disease)

This resulted in 3348 subjects.

We then used a greedy-matching algorithm to best match the risk factors to render a control cohort of 39 subjects, baseline demographics in Table 1.

This was added to the text for clarity.

C. Lines 134-49.

D. "We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive) ultrasound studies including subjects from a single United States referral center with suspected PAS and confirmed on hysterectomy specimen between 2016 (when the EW-AIP checklist was published

and adopted at our institution) and 2020. We identified a 1:1 control cohort of subjects without PAS clinically or on the final pathology report. In an effort to control for expected bias influenced by clinical risk factors for PAS, we best-matched the control cohort using a greedy-matching algorithm for pre-defined clinical characteristics listed in the ACOG Obstetric Care Consensus^[3], including placenta previa, number of prior cesarean deliveries, prior dilation and curettage (D&C), and in vitro fertilization (IVF). Additionally, we matched clinical characteristics influencing image quality including body mass index (BMI), multiple gestation, and gestational age at the time of the ultrasound. **Thus, the control cohort was created by including subjects with imaging conducted at the same diagnostic center and cesarean delivery conducted at the same labor and delivery during the same timeframe, then excluded those with PAS on final pathology or on review of operative note. The last step was matching the pre-defined clinical characteristics as the disease cohort.**

REVIEWER 3, POINT #4

- A. *Does final pathology include lower microscopic grades of accreta, such as microscopic accreta or adherent myometrial fibers at the basal plate? Were pathology reports of slides examined? If so, by whom?*
- B. For pathologic definitions, we used *Hecht JL et al²* as a guide, which states “[Basal Plate myometrial fibers] are often detected incidentally on delivered placentas based on random sectioning (with no associated gross findings), so quantitation based on gross features is difficult”. The pathologic definition is reference #12 in the manuscript.

Therefore, we did not include microscopic accreta or BPMF in the primary outcome, and included disease denoted as accreta, increta, or percreta. The intent of the checklist was to detect clinically significant PAS, rather than incidental PAS.

The pathologic reports were reviewed by the lead author. **We have added this to the manuscript for clarity.**

- C. Lines 137-40
- D. We retrospectively identified a 1:1 control cohort of subjects without PAS clinically or on the final pathology report (**incidental diagnoses on placental specimens were not included**)

REVIEWER 3, POINT #5

- A. *Given that controls were examined for reasons other than the PAS checklist, were images reviewed by the first author to ensure that the views and studies necessary to capture all the checklist items were present?*
- B. See Reviewer #1, Point #4, above

REVIEWER 3, POINT #6

² Hecht JL, Baergen R, Ernst LM, et al. 2020. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: recommendations from an expert panel. *Modern Pathology*. 2020;33(12):2382-2396. doi:10.1038/s41379-020-0569-1

- A. *The difference in image numbers presents a problem. The author's provide a reasonable explanation (although see below about line 151 vs. 299), but I remain concerned that MFMs reviewing images may have taken cues from the number and type of images in guessing whether the study was for suspected accreta. It may be worth asking reviewers whether they were able to make such a guess, but I am unable to identify an appropriate design for such a post-hoc study. I assume the interval image review and submission has been lengthy, which would make responses less reliable.*
- B. Yes, we agree this is an anticipated limitation and due to the retrospective design. This is clearly laid out in the limitations. As the reviewer presumes, the interval between review (September 2021) and submission is lengthy, rendering the responses unreliable. However, it is a prudent idea for prospective study design.
- C. Lines 337-42.
- D. “Second, there were more images within the PAS cohort than the control cohort, likely reflecting the sonographers internal assessment as they were obtaining images for interpretation or requested additional focus. While the sonologists in this study were blinded to the clinical outcome, a potential bias is introduced. The lead author intentionally did not control this known discrepancy in advance to avoid introducing a selection bias by “cherry picking” included images for blinded review (aside from removing non-placental images).

REVIEWER 3, POINT #7

- A. *Line 94 - Regarding the 53% suspicion, what did suspicion entail and what was the definition of PAS (clinical? microscopic? at hysterectomy?)?*
- B. In the MFMU article referenced in the manuscript³, among the 158 subjects with PAS (diagnosed clinically by review by two blinded co-authors), 84 (53.2%) had a suspected diagnosis and 74 were unsuspected (46.8%).
- C. N/a
- D. N/a

REVIEWER 3, POINT #8

- A. *Line 151 - It's stated that images were selected. However line 299 states the first author did not 'cherry pick' specific images or studies. Please clarify.*
- B. The lead author included images of the placenta, cervix, and cord insertion for efficiency of sonologist review (i.e. excluded fetal images). Among the placental images included, none were excluded. **This was clarified in the text.**
- C. Lines 340-2.

³ Bailit, J. L. , Grobman, W. A. , Rice, M. M. , Reddy, U. M. , Wapner, R. J. , Varner, M. W. , Leveno, K. J. , Iams, J. D. , Tita, A. T. , Saade, G. , Rouse, D. J. & Blackwell, S. C. (2015). Morbidly Adherent Placenta Treatments and Outcomes. *Obstetrics & Gynecology*, 125 (3), 683-689. doi: 10.1097/AOG.0000000000000680.

- D. The lead author intentionally did not control this known discrepancy in advance to avoid introducing a selection bias by “cherry picking” included images for blinded review (**aside from removing non-placental images**).

REVIEWER 3, POINT #9

- A. *Line 202 - Since the study is retrospective I assume patients were not specifically recruited for this study - please confirm (similar language in Figure 1)*
- B. Subjects with PAS (the disease cohort) was prospectively enrolled as part of an institutional registry. The control subjects were retrospectively identified. **This was clarified in the text.**
- C. Lines 134-8
- D. “We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive) ultrasound studies including subjects **prospectively enrolled** at a single United States referral center with suspected PAS and confirmed on hysterectomy specimen between 2016 (when the EW-AIP checklist was published and adopted at our institution) and 2020. **We retrospectively identified** a 1:1 control cohort of subjects...”

REVIEWER 3, POINT #10

- A. *Line 223-224 - Is mild defined as accreta?*
- B. Yes. **This is clarified in the text.**
- C. Lines 259-62.
- D. When excluding mild cases (or histologic accreta (n=10), and assessing only histologic increta and percreta) the sensitivity (95% CI) increased to 84.7% (73.6%-96.4%) and specificity remained the same with a narrowed CI, 92.0% (83.2%-99.9%).

REVIEWER 3, POINT #11

- A. *Lines 238-245 - Consider reporting sens/spec of individual components (vs. kappa). Consider reporting correlation between components.*
- B. We considered reporting sensitivity/specificity in the development of the study design due to increased familiarity to this statistic among the clinical community. However, we ultimately made the sensitivity / specificity of the checklist as the *primary outcome* in order to assess the validity of the checklist (i.e. does it accurately predict histologic PAS?), and *reported a kappa* as the *secondary outcome* in order to answer the question of reliability (i.e. how consistent are the reviewer responses?). The sensitivity/specificity of individual components of the checklist have been previously studied⁴, and our secondary outcomes focused on their pragmatic application

⁴ Skupski, D. W., Duzyj, C. M., Scholl, J., Perez-Delboy, A., Ruhstaller, K., Plante, L. A., Hart, L. A., Palomares, K. T. S., Ajemian, B., Rosen, T., Kinzler, W. L., Ananth, C., & Perinatal Research Consortium (2022). Evaluation of classic and novel ultrasound signs of placenta accreta spectrum. *Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 59(4), 465–473. <https://doi.org/10.1002/uog.24804>

across institutions. Since the clinical reader may be unfamiliar with kappa, we placed this in plain language in the text and on the Table 4.

C. Table 4; Lines 201-7

D. Table 4: “To check agreement between sonologists’ individual (binary) responses (e.g., loss of clear zone) and the true case/control status we used Cohen’s kappa. This provided us with a numerical summary between -1 and 1 for each sonologist, where 0 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1 indicates perfect disagreement.”

Lines 201-7: For secondary outcomes, we analyzed the interrater reliability of the sonologists’ responses, using Kappa statistics to compute an interrater correlation coefficient (ICC) to assess the agreement for each characteristic between the 9 sonologists. Additionally, to compute the aggregate sonologists’ responses for individual characteristics to the true histologic diagnosis of PAS, we used Cohen’s Kappa, which provided a numerical summary between -1 and 1, where 0 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1 indicates perfect disagreement.

REVIEWER 3, POINT #12

A. *Lines 243-245 - It may be worth digging into fellow performance a bit more. The fellows are doing well in the overall diagnosis but not as well for individual items. This suggests some redundancy in the items (thus correlations are useful). This could suggest a lack of familiarity. If the fellows systematically undercall or overcall specific findings that may point to areas of focus in education.*

B. The primary outcome was to assess diagnostic performance of the checklist; the learning curve was a secondary outcome. With 2 out of 9 sonologists fellows, it would be difficult to interpret fellow responses with a robust conclusion although this question is certainly for further research. We have added this to the discussion.

C. Lines 322-5.

D. “An interesting finding was that responses from the MFM fellows did not significantly impact overall predictive performance, suggesting that this checklist may have an early learning curve if adopted as a part of MFM training. While the independent items within the checklist had more variability, the overall impression was similar to experienced clinicians. Components of the checklist may be helpful for training for familiarity and recognition, but the overall impression is the most relevant. Checklists have emerged for the management of complex conditions to standardize evidence- or consensus-based processes and promote high quality and consistent care. Accordingly, SMFM has created a checklist for surgical planning for anticipated and unexpected PAS^[15]. Establishing a clinically validated checklist for the systematic evaluation of placenta and uterus is imperative for education, training, and research.”

REVIEWER 3, POINT #13

A. *Table 1 - I assume BMI is at time of exam?*

B. BMI was calculated at the new prenatal visit. This was added to the text for clarity.

C. Lines 144-5

- D. “Additionally, we matched clinical characteristics influencing image quality including body mass index (BMI) **at first prenatal visit**, multiple gestation, and gestational age at the time of the ultrasound.”

REVIEWER 4, POINT #1

- A. *Thank you for the opportunity to review this manuscript; understanding the accuracy of diagnostic tools for PAS is highly important in allocation of hospital resources and preparing for potentially complex cases. PAS research is challenging to conduct in an optimal, prospective manner and I appreciate both the efforts taken by the authors to contribute in this arena and their acknowledgment of their limitations.*

How many of the PAS cases were initially identified or suspected on ultrasound prior to delivery? I see the MFMU rate of 53% suspected prior to delivery, but I'm curious about the rate in this cohort?

- B. We queried our database of histologic-confirmed PAS cases during 2016-2020 (the same timeframe as the inclusion criteria for the present manuscript), and there were 62 cases at the same institution. 39 of these cases were suspected; thus **62.9% cases were anticipated** and confirmed on histology.

REVIEWER 4, POINT #2

- A. *Did you assess provider familiarity with the EW-AIP checklist? Did all providers routinely use this checklist prior to the study or was it new for certain providers?*
- B. Prior familiarity with the checklist was not specifically required by the sonologists, although given the checklist items were published as part of an SMFM consult series, familiarity with the components within the checklist was expected.⁵
- C. Lines 177-8.
- D. The 9 sonologists were from 5 United States referral centers (7 MFM faculty and 2 MFM fellows), recruited by email after an annual professional conference, and **prior familiarity with the EW-AIP checklist was not required**

REVIEWER 4, POINT #3

- A. *You mention that not all subjects with anticipated PAS are managed with hysterectomy at your institution, something that may affect the severity of the disease in the cohort of cases with histologic confirmation. Could you add in the criteria used to determine conservative management vs. hysterectomy at your institution to better understand the disease spectrum that would be seen on histologic specimens?*
- B. See Reviewer #1, Point #1, above.

⁵ Shainker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, et al. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum. Am J Obstet Gynecol. 2021. 224(1):B2-B14.

- 1 **Manuscript title:** Validation of a sonographic checklist for the detection of histologic
2 placenta accreta spectrum.
3
- 4 **Condensation:** A sonographic checklist for reporting suspected placenta accreta spectrum
5 has a positive likelihood ratio of 9.6 to detect (and 0.3 negative likelihood
6 ratio to exclude) histologic disease.
7
- 8 **Short title:** Sonographic checklist to predict placenta accreta spectrum
9
- 10 **AJOG at a Glance:** **A. Why was this study conducted?**
11
12 An expert consensus checklist was developed in 2016 to standardize
13 sonographic reporting of suspected placenta accreta spectrum and
14 reduce the risk of unanticipated disease. However, the diagnostic
15 performance of the checklist is not known.
16
- 17 **B. What are the key findings?**
18
19 The checklist has a positive and negative likelihood ratio of 9.6 and
20 0.3, respectively, and its sensitivity and specificity improves with more
21 severe histologic disease.
22
- 23 **C. What does this study add to what is already known?**
24
25 This study provides diagnostic accuracy to support a standardized
26 sonographic checklist for use in clinical interpretation, research, and
27 training for placenta accreta spectrum.
28
- 29 **Conflict of Interest:** The authors report no conflicts of interest.
30
- 31 **Keywords:** Abnormal placentation, abnormally adherent placenta, antenatal diagnosis,
32 checklist, delivery planning, morbidly adherent placenta, multidisciplinary
33 team, placental imaging, sonographic imaging, ultrasound
34
- 35
36
37
38
39
40

41 **Abstract**

42 Background: To standardize research terminology and reduce unanticipated placenta accreta
43 spectrum (PAS), the European Working Group for Abnormally Invasive Placenta (EW-AIP)
44 developed a consensus checklist for reporting PAS suspected on antenatal ultrasound. The
45 diagnostic accuracy of the EW-AIP checklist has not been assessed.

46 Objective: To test the performance of the EW-AIP sonographic checklist in predicting histologic
47 PAS.

48 Study Design: This is a multi-site, blinded, retrospective review of transabdominal ultrasound
49 studies performed between 26-32 weeks gestation for subjects with histologic PAS between
50 2016-2020. We ~~planned~~ matched a 1:1 control cohort of subjects without histologic PAS. To
51 reduce reader bias, we matched the control cohort for known risk factors including previa,
52 number of prior cesarean deliveries, prior dilation and curettage (D&C), in vitro fertilization
53 (IVF), and clinical factors affecting image quality including multiple gestation, body mass index
54 (BMI) and gestational age at the ultrasound. Nine sonologists from 5 referral centers, blinded to
55 the histologic outcomes, interpreted the randomized ultrasound studies using the EW-AIP
56 checklist. The primary outcome was the sensitivity and specificity of the checklist to predict
57 PAS. Two separate sensitivity analyses were performed: 1) we excluded subjects with mild
58 disease (i.e. only assessed subjects with histologic increta and percreta); 2) we excluded
59 interpretations from the 2 most junior sonologists.

60 Results: 78 subjects were included (39 PAS, 39 matched control). Clinical risk factors and image
61 quality markers were statistically similar between cohorts. The checklist sensitivity (95%
62 Confidence Interval, CI) was 76.6% (63.4%-90.6%) and specificity (95% CI) was 92.0%
63 (63.4%-99.9%), with a positive and negative likelihood ratio of 9.6 and 0.3, respectively. When

64 we excluded subjects with mild PAS disease, the sensitivity (95% CI) increased to 84.7%
65 (73.6%-96.4%) and specificity was unchanged at 92.0% (83.2%-99.9%). Sensitivity and
66 specificity were unchanged when the interpretations from the 2 most junior sonologists were
67 excluded.

68 Conclusion: The 2016 EW-AIP checklist for interpreting PAS has a reasonable performance in
69 detecting and excluding histologic placenta accreta spectrum.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87 **Introduction**

88 The incidence of placenta accreta spectrum (PAS) is rising, and it is now the leading
89 indication for puerperal hysterectomy^[1]. Management typically includes a scheduled, late
90 preterm delivery by a multidisciplinary team^[2]. Unanticipated PAS deliveries put pregnant
91 patients at highest risk for blood transfusion, ICU admission, and death^[3]. Thus, antenatal
92 diagnosis is prerequisite for surgical planning to reduce maternal morbidity and
93 mortality. Despite this necessity, a recent Maternal-Fetal Medicine Unit Network study found
94 that PAS was suspected in only 53% of subjects prior to delivery^[4].

95 The mainstay for antenatal PAS diagnosis is ultrasound. However, ultrasound is operator
96 dependent, and limited by a prior lack of standardized definitions of PAS ultrasound markers.
97 Additionally, a patient's *a priori* risk for PAS, based on historical characteristics, influences
98 interpretation of ultrasound studies. Therefore, objective assessment of PAS imaging
99 characteristics is challenging for prospective research^[5].

100 Given the need to standardize PAS ultrasound markers, in 2016 the European Working
101 Group on Abnormally Invasive Placenta (EW-AIP) produced a consensus checklist for
102 ultrasound assessment of placentation^[6]. The checklist was developed by an online
103 questionnaire of 50 international experts, and a list of 11 sonographic markers was derived from
104 expert opinion. Two years later, both the International Federation of Gynecology and Obstetrics
105 (FIGO) and the Society for Maternal Fetal Medicine (SMFM) endorsed the sonographic
106 characteristics within the checklist^[7,8]. While the EW-AIP checklist is derived from and
107 endorsed by several professional societies, the clinical performance of the checklist itself has not
108 been assessed.

109 Our objective was to assess the diagnostic accuracy of the Maternal-Fetal Medicine
110 (MFM) sonologist's overall impression of PAS using the EW-AIP checklist, and to further
111 evaluate the interrater reliability and diagnostic performance for each of the characteristics.

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132 Materials and Methods

133 We conducted a multi-site, blinded, retrospective review of 26-32 week (inclusive)
134 ultrasound studies ~~foincludingr~~ subjects prospectively enrolled at ~~from~~ a single United States
135 referral center with suspected PAS and confirmed on hysterectomy specimen between 2016
136 (when the EW-AIP checklist was published and adopted at our institution) and 2020. We
137 retrospectively identified a 1:1 control cohort of subjects without PAS clinically or on the final
138 pathology report, imaged antenatally at the same diagnostic center and undergoing cesarean
139 delivery at the same hospital as the PAS subjects (incidental diagnoses on placental specimens
140 were not included). In an effort to control for expected bias influenced by clinical risk factors
141 for PAS, we best-matched the control cohort using a greedy-matching algorithm for pre-defined
142 clinical characteristics listed in the ACOG Obstetric Care Consensus^[3], including placenta
143 previa, number of prior cesarean deliveries, prior dilation and curettage (D&C), and in vitro
144 fertilization (IVF). Additionally, we matched clinical characteristics influencing image quality
145 including body mass index (BMI) at first prenatal visit, multiple gestation, and gestational age at
146 the time of the ultrasound. Thus, the control cohort was created by including subjects with
147 imaging conducted at the same diagnostic center and cesarean delivery conducted at the same
148 labor and delivery during the same timeframe, then excluded those with PAS on final pathology
149 or on review of operative note. The last step was matching the pre-defined clinical
150 characteristics as the disease cohort.

151 Ultrasounds studies from 26-32 weeks gestation were chosen for review, as this timing
152 was the institutional standard for follow up for suspected abnormal placentation diagnosed
153 during routine anatomy scan. Regardless of the disease severity, subjects with anticipated PAS
154 were cared for by a multidisciplinary care team and, with intraoperative confirmation and the

155 patient's consent, adherent placenta was managed with cesarean hysterectomy. Of note, while
156 not all subjects with ~~anticipated~~-PAS may have been managed with hysterectomy at our
157 institution, a hysterectomy was required as part of the present study design as histology was the
158 primary outcome to test the sonographic checklist.

159 After the PAS and control cohorts were created, the lead author (who did not participate
160 in interpreting the ultrasound studies) selected transabdominal ultrasound images and cine clips
161 of the images of the placenta, cervix, and placental cord insertion obtained during a detailed
162 second trimester ultrasound (CPT 76811) or follow up ultrasound (CPT 76816). Selected images
163 included both still and cine clips, and greyscale and color Doppler images – no dedicated image
164 of the placenta, cervix, or cord insertion was excluded, as the EW-AIP checklist did not have a
165 prescribed number of images. –The ultrasound images were de-identified, randomized, and
166 then interpreted by 9 Maternal-Fetal Medicine (MFM) sonologists blinded to final histology.
167 The blinded sonologists were aware that the ultrasound series included matched controls, but
168 were not aware of the specific ratio for matching. The 9 sonologists were from 5 United States
169 referral centers (7 MFM faculty and 2 MFM fellows), recruited by email after an annual
170 professional conference, and prior familiarity with the EW-AIP checklist was not required.^[9]
171 For each ultrasound, the sonologists were provided the gestational age and the matched clinical
172 characteristics from the Obstetric Care Consensus^[3], such as number of prior cesarean deliveries
173 or prior D&Cs. To simulate a workflow at an antenatal diagnostic center, 5 minutes were
174 suggested to review each ultrasound and the sonologists were permitted to move between images
175 and cine clips as necessary. Consistent with the EW-AIP checklist, the nine sonologists could
176 choose “present”, “absent”, or “unsure” for each sonographic sign, and then prompted to predict
177 whether there was a low or high probability of PAS on pathology. To preserve integrity of

178 statistical analysis, each sonologist was required to review 100% of the ultrasounds studies, or
179 their responses were discarded.

180 Baseline demographics of the PAS and control cohorts were assessed using Chi-Square
181 or ANOVA F-Test, depending on whether the demographic was binary or continuous,
182 respectively. For the primary outcome, to measure the strength of agreement between
183 sonologists' interpretation and histologic diagnosis, a dichotomous sensitivity and specificity
184 table was created using the sonologists' aggregate overall impression. Two separate sensitivity
185 analyses were performed: 1) we excluded subjects with mild disease (i.e. excluding subjects with
186 histologic accreta and only including subjects with histologic increta and percreta on
187 hysterectomy specimen); 2) we excluded interpretations from the 2 MFM fellows who were most
188 junior in experience with ultrasound interpretation. We performed these analyses to assess how
189 disease severity and sonologist experience affected the performance of the checklist.

190 For secondary outcomes, we analyzed the interrater reliability of the sonologists'
191 responses, using Kappa statistics to compute an interrater correlation coefficient (ICC) to assess
192 the agreement for each characteristic between the 9 sonologists. Additionally, to compute the
193 aggregate sonologists' responses for individual characteristics to the true histologic diagnosis of
194 PAS, we used Cohen's Kappa, which provided a numerical summary between -1 and 1, where 0
195 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1
196 indicates perfect disagreement.

197 The images were anonymized and exported from the clinical picture archiving and
198 communications system (Viewpoint 6.11, General Electric) onto an encrypted, cloud-based
199 content management platform (Box Service, 2022). The checklist for each subject was completed
200 on REDCap 12.0.2. Statistical software used was SAS 9.4 (SAS Institute, Cary, NC). The study

201 was approved by the institutional review board at each of the five participating institutions and a
202 data transfer agreement was executed to facilitate transfer of the de-identified images. The de-
203 identified images and code used for analysis are available upon request for either research or
204 education purposes.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224
225

226 **Results**

227 Subject recruitment is demonstrated in Figure 1. In total, there were 39 subjects with
228 PAS that met inclusion criteria including: a) performance of an ultrasound between 26-32 weeks
229 gestation, b) hysterectomy performed between 2016-2020 with histology confirming PAS. After
230 pooling the PAS cohort's pre-defined risk factors, the 1:1 control cohort was identified by
231 querying 3,348 subjects who had a cesarean delivery at the same center during the same time
232 period, but without PAS suspected clinically or on final pathology. Baseline demographics
233 between the PAS and control cohorts were statistically similar, including presence of placenta
234 previa on ultrasound (64.1% vs 59.0%, $p=0.64$), median (25th, 75th percentile) number of prior
235 cesarean deliveries (2 [1, 3], for both cohorts, $p>0.99$), prior D&Cs (23.1% vs 25.6%, $p=0.79$)
236 and IVF conception (2.6% for both cohorts, $p>0.99$). Furthermore, factors influencing image
237 quality were statistically similar including BMI, multiple gestation, and gestational age of
238 ultrasound (Table 1). Of note, although study sonologists were unaware of this fact, there were
239 more images for PAS subjects than control subjects (median 23.0 [13.0, 33.0] versus 16.0 [9.0,
240 20.0], respectively, $p=0.002$).

241 Each of the 9 sonologists completed the checklist for all subjects. The median (25th, 75th
242 percentile) years of MFM experience was 5.0 (2.8, 8.0), with a range of 1-22. Seven sonologists
243 were practicing MFM faculty (6 board-certified, 1 board-eligible), and 2 were active MFM
244 fellows.

245 Primary outcomes are listed in Table 2. The sensitivity (95% Confidence Interval, CI) of
246 the EW-AIP checklist detecting histologic PAS was 76.6% (63.4%-90.6%) and specificity (95%

247 CI) was 92.0% (63.4%-99.9%), yielding a positive likelihood ratio to detect PAS of 9.6, and a
248 negative likelihood ratio to exclude PAS of 0.3. When excluding mild cases ~~(~~or histologic
249 accreta (n=10), and assessing only histologic increta and percreta~~)~~, the sensitivity (95% CI)
250 increased to 84.7% (73.6%-96.4%) and specificity remained the same with a narrowed CI, 92.0%
251 (83.2%-99.9%). When excluding the responses of the two MFM fellows, the sensitivity and
252 specificity were negligibly affected, 78.0% (64.8%-91.2%) and 93.0% (85.0%-99.9%),
253 respectively.

254 For secondary outcomes, the interrater classification coefficient (which reflects the
255 degree of correlation and agreement between measurements among 9 sonologists) is shown in
256 Table 3. The two characteristics with the most agreement between sonologists was abnormal
257 placental lacunae (0.4) and uterovesical hypervascularity (0.41), indicating good reliability
258 between reviewers. Bladder wall interruption (0.19) and focal exophytic mass (0.05) were noted
259 least consistently, indicating poor reliability. In the sensitivity analysis, sonologist agreement for
260 each of the 11 characteristics increased with more severe histologic disease. Additionally, when
261 excluding the responses of the most junior sonologists, there was an increase in agreement for
262 each of the 11 characteristics, even if this did not change their overall diagnostic impression.

263 Table 4 lists the performance of individual characteristic against histologic PAS, or in
264 other words, the predictive value of histologic PAS if the individual characteristic was
265 identified. Each of the characteristics had a positive association with histological PAS, with the
266 highest agreement being myometrial thinning (0.56), loss of clear zone (0.55), and ~~bladder wall~~
267 ~~interruption (0.34)~~ ~~placental bulge (0.48)~~. The least correlated with severe disease was the
268 parametrial involvement, with a kappa of 0.05. Similarly, the agreement between sonographic

269 characteristic and true PAS diagnosis improved with more severe disease, as well as excluding
270 the responses from the two junior sonologists.

271

272 **Discussion**

273 Principal Findings

274 Using a consensus expert opinion initially proposed in 2016 by EW-AIP and endorsed in
275 2018 by FIGO and SMFM, we assessed the clinical performance of an ultrasound checklist for
276 the histologic diagnosis of PAS. The sensitivity (95% CI) was 76.6% (63.4%-90.6%) and
277 specificity (95% CI) was 92.0% (63.4%-99.9%) in predicting PAS, yielding a positive likelihood
278 ratio to detect PAS of 9.6, and a negative likelihood ratio to exclude PAS of 0.3. The
279 performance of the checklist to predict histologic PAS improved with more severe disease
280 (increta and percreta) and maintained a strong performance when employed by less experienced
281 sonologists (MFM fellows).

282 Results in the context of what is known

283 As our understanding of the pathophysiology of PAS evolves from a model centering on
284 *placental-invasion* to a model of *uterine-dehiscence*^[10], reporting radiologic, clinical, or
285 pathologic PAS has moved away from categorical “accreta”, “increta” and “percreta”
286 terminology to a more descriptive approach. For example, in 2018 FIGO sought to standardize
287 intraoperative findings with a clinical criteria that describes pelvic involvement of
288 placentation^[11] rather than using categorical terms. Additionally, a consensus panel of clinical
289 pathologists have replaced the categorical terminology to a 10 characteristic, descriptive grading
290 system^[12]. Similarly, driven by the need to standardize sonographic PAS markers, multiple
291 professional societies have called for a systematic approach to the evaluation of the uterus and

292 placenta. EW-AIP put forth a proposed checklist in 2016, reviewing 23 manuscripts and drafting
293 a list of 11 PAS ultrasound markers (6 markers are greyscale, 4 are 2D color Doppler, and 1 is
294 3D power Doppler)^[6]. The present study now provides clinical performance outcomes for the
295 expert-consensus checklist put forward by EW-AIP.

296 Research implications

297 Studies assessing predictive value of ultrasound markers for PAS are limited by small
298 sample sizes, retrospective designs without a control cohort, and heterogenous definitions of
299 PAS. For example, the sensitivity and specificity of hypervascular uterovesical interface ranges
300 widely from 11-100% and 36-100% respectively^[13,14]. Given the broad range of predictive
301 values for each characteristic within the checklist, the EW-AIP consensus stresses that all
302 markers should be systematically assessed and unambiguously reported until further research
303 clarifies their individual utility. Therefore, the primary outcome of this study was to report the
304 performance of the “bundle” of sonographic markers in a checklist format that may be readily
305 adopted by antenatal diagnostic centers.

306 An interesting finding was that responses from the MFM fellows did not significantly
307 impact overall predictive performance, suggesting that this checklist may have an early learning
308 curve if adopted as a part of MFM training. While the independent items within the checklist
309 had more variability, the overall impression was similar to experienced clinicians. Components
310 of the checklist may be helpful for training in familiarity and recognition, but the overall
311 impression is the most clinically relevant. Checklists have emerged for the management of
312 complex conditions to standardize evidence- or consensus-based processes and promote high
313 quality and consistent care. Accordingly, SMFM has created a checklist for surgical planning for

314 anticipated and unexpected PAS^[15]. Establishing a clinically validated checklist for the
315 systematic evaluation of placenta and uterus is imperative for education, training, and research.

316 Strengths and limitations

317 There are two key, related limitations to this study. Although the study involved blinded
318 interpretations by sonologists from multiple institutions, it is retrospective in design. Therefore,
319 images were not systematically procured in a checklist manner to capture or exclude components
320 of the checklist itself. We suspect that this limitation is pertinent to the secondary outcomes,
321 assessing the individual characteristics of the checklist. We therefore recommend caution in
322 interpreting Table 4 as these may underreport the performance against the true PAS
323 diagnosis. Second, there were more images within the PAS cohort than the control cohort, likely
324 reflecting the sonographers internal assessment as they were obtaining images for interpretation
325 or requested additional focus. While the sonologists in this study were blinded to the clinical
326 outcome, a potential bias is introduced. The lead author intentionally did not control this known
327 discrepancy in advance to avoid introducing a selection bias by “cherry picking” included
328 images for blinded review (aside from removing non-placental images).

329 There are four strengths to the study. First, the use of a control cohort matched
330 comprehensively for PAS risk factors is an effort to neutralize the impact of knowing the
331 patient’s clinical history before reading the images. Mimicking real world ultrasound reading,
332 sonologists had the basic clinical information prior to reading the scan, such as number of prior
333 cesarean or IVF conception, and the clinical characteristics were comparable between the PAS
334 and control cohorts. Second, both the PAS and control cohort were selected from the same
335 referral center, therefore standardizing variables such as sonographer education, image
336 procurement, and ultrasound machines used. Additionally, to reduce the risk of recall bias,

337 images were blinded and reviewed by sonologists from four external institutions that did not
338 participate in the subjects' clinical care and therefore had never seen the images
339 previously. Lastly, the planned sensitivity analysis assessed the impact of disease severity as
340 well as sonologist training in order to assess potential uptake of the checklist as a part of clinical
341 care or education.

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363 Conclusion

364 Our multi-site study has assessed the diagnostic accuracy of an ultrasound checklist for

365 the detection of placenta accreta spectrum, with a high likelihood ratio. The routine

366 incorporation of this checklist may contribute to decreased unanticipated PAS cases and timely

367 referral to PAS centers, as well as standardize research terminology.

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386 **References:**

- 387 1. Machado LS. Emergency peripartum hysterectomy: Incidence, indications, risk factors
388 and outcome. *N Am J Med Sci*, 2011. 3(8):358-61.
- 389 2. ACOG, Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. *Obstet Gynecol*,
390 2018. 132(6):1519-1521.
- 391 3. Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, et al. Maternal outcomes
392 in unexpected placenta accreta spectrum disorders: single-center experience with a
393 multidisciplinary team. *Am J Obstet Gynecol*, 2019. 221(4):337 e1-337e5.
- 394 4. Bailit JL, Grobeman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al for
395 Eunice Kennedy Shriver National Institute of Child Health and Human Development
396 Maternal-Fetal Medicine Units Network. Morbidly adherent placenta treatments and
397 outcomes. *Obstet Gynecol*, 2015. 125(3):683-689.
- 398 5. Bhide A, Sebire N, Abuhamad A, Acharya G, Silver RM. Morbidly adherent placenta:
399 the need for standardization. *Ultrasound Obstet Gynecol*, 2017. 49(5):559-563.
- 400 6. Alfirevic Z, Tang AW, Collins SL, Robson SC, Palacios-Jaraquemada J for the Ad Hoc
401 International AIP Expert Group. Pro forma for ultrasound reporting in suspected
402 abnormally invasive placenta (AIP): an international consensus. *Ultrasound Obstet*
403 *Gynecol*, 2016. 47(3): p. 276-8.
- 404 7. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J for the FIGO Placenta Accreta
405 Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on
406 placenta accreta spectrum disorders: Prenatal diagnosis and screening. *Int J Gynaecol*
407 *Obstet*, 2018. 140(3):274-280.
- 408 8. Shainker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, et al.
409 Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum
410 Ultrasound Marker Task Force: Consensus on definition of markers and approach to the
411 ultrasound examination in pregnancies at risk for placenta accreta spectrum. *Am J Obstet*
412 *Gynecol*, 2021. 224(1):B2-B14.
- 413 9. Duke Obstetrics & Gynecology. Validation of ISUOG consensus for reporting placenta
414 accreta spectrum. 2021 September 7. [Video]. YouTube. <https://www.scribbr.com/apa-examples/youtube/#:~:text=To%20cite%20a%20YouTube%20video%20in%20APA%20Style%2C%20you%20include,a%20link%20to%20the%20video>.
- 415
416
- 417 10. Einerson BD, Comstock J, Silver RM, Branch DW, Woodward PJ, Kennedy A. Placenta
418 Accreta Spectrum Disorder: Uterine Dehiscence, Not Placental Invasion. *Obstet Gynecol*,
419 2020. 135(5): 1104-1111.
- 420 11. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J. FIGO consensus guidelines on
421 placenta accreta spectrum disorders: Epidemiology. *Int J Gynaecol Obstet*, 2018. 140(3):
422 265-273.
- 423 12. Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E, et al.
424 Classification and reporting guidelines for the pathology diagnosis of placenta accreta

- 425 spectrum (PAS) disorders: recommendations from an expert panel. *Mod Pathol*, 2020.
426 33(12):2382-2396.
- 427 13. Bowman ZS, Eller AG, Kennedy AM, Richards DS, Winter TC, Woodward PJ, Silver
428 RM. Accuracy of ultrasound for the prediction of placenta accreta. *Am J Obstet Gynecol*,
429 2014. 211(2):177 e1-7.
- 430 14. Japaraj RP, Mimin TS, Mukudan K. Antenatal diagnosis of placenta previa accreta in
431 patients with previous cesarean scar. *J Obstet Gynaecol Res*, 2007. 33(4):431-7.
- 432 15. Society for Maternal-Fetal Medicine Patient and Quality Safety Committee. Preoperative
433 planning form for suspected morbidly adherent placenta. 2020.
434 <https://www.smfm.org/checklists-and-safety-bundles>.
435
436
437
438

1 **Table 1: Baseline demographics between PAS and 1:1 matched control cohort**

	PAS on hysterectomy specimen (n=39)	Control cohort without PAS (n=39)	p value
Placenta previa	25 (64.1%)	23 (59.0%)	0.64 ¹
Number of prior cesarean	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	>0.99 ²
IVF	1 (2.6%)	1 (2.6%)	>0.99 ¹
Prior D&C	9 (23.1%)	10 (25.6%)	0.79 ¹
BMI (kg/m²)	29.3 (24.5, 36.1)	28.5 (22.6, 37.6)	0.82 ²
Multiple gestation	1 (2.6%)	1 (2.6%)	>0.99 ¹
US gestational age (weeks)	28.0 (26.0, 29.0)	29.0 (26.0, 29.0)	0.93 ²
Number of images per US	23.0 (13.0, 33.0)	13.0 (9.0, 20.0)	0.002 ²
<u>Indication for US in control cohort</u>			
<u>Placental reassessment</u>		<u>30 (76.9%)</u>	
<u>Fetal Indication</u>		<u>6 (15.4%)</u>	
<u>Anatomy</u>		<u>3 (7.7%)</u>	
Final pathology			<0.001 ¹
No PAS	0 (0.0%)	39.0 (100.0%)	
Accreta	10 (26.3%)	0 (0.0%)	
Increta or percreta	29 (76.3%)	0 (0.0%)	
Binary variables are represented number (%) Continuous variables are median (25 th percentile, 75 th percentile)			
IVF: <i>in vitro</i> fertilization; US: ultrasound; BMI: body mass index; PAS: placenta accreta spectrum			
¹ Chi-square; ² ANOVA F-Test			

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Formatted: Font: Not Bold

3
4
5
6
7
8
9
10
11
12
13
14
15

Table 2: Primary outcome – performance of EW-AIP checklist on detection of PAS

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Sensitivity	76.7% (63.4%-90.6%)	84.7% (73.6%-96.4%)	78.0% (64.8%-91.2%)
Specificity	92.0% (63.4%-99.9%)	92.0% (83.2%-99.9%)	93.0% (85.0%-99.9%)
Positive Likelihood Ratio	9.6	10.6	11.8
Negative Likelihood Ratio	0.3	0.2	0.2
Sensitivity and specific above measured with 95% confidence interval			

16
17
18
19
20
21

Table 3: Secondary outcome – interobserver variability of individual characteristics

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Loss of clear zone	0.25	0.49	0.50
Myometrial thinning	0.29	0.53	0.58
Abnormal placental lacunae	0.40	0.54	0.57
Bladder wall interruption	0.19	0.34	0.35
Placental bulge	0.22	0.48	0.50
Focal exophytic mass	0.05*	0.12*	0.10
Uterovesical hypervascularity	0.41	0.62	0.61
Subplacental hypervascularity	0.33	0.62	0.48
Bridging vessels	0.23	0.44	0.44
Placental lacunae feeder vessels	0.30	0.43	0.40
Parametrial involvement	0.23	0.02*	0.03*

*Mixed-effects model did not converge.

Inter-characteristic correlation (ICC) with no restrictions is 0.71 which indicates a reasonable sonologist-to-sonologist reliability. Estimates closer to this number indicate more reliable performance measures.

22
23

24
25
26
27
28
29

Table 4: Secondary outcome – performance of individual characteristics

	All cases (n=78)	Excluding histologic accreta (n=68)	Excluding 2 MFM fellows (n=78)
Loss of clear zone	0.55	0.63	0.59
Myometrial thinning	0.56	0.64	0.61
Abnormal placental lacunae	0.44	0.52	0.45
Bladder wall interruption	0.34	0.45	0.36
Placental bulge	0.48	0.59	0.54
Focal exophytic mass	0.11	0.17	0.13
Uterovesical hypervascularity	0.44	0.49	0.45
Subplacental hypervascularity	0.33	0.38	0.34
Bridging vessels	0.35	0.41	0.35
Placental lacunae feeder vessels	0.23	0.32	0.30
Parametrial involvement	0.049	0.045	0.12
To check agreement between sonologists' individual (binary) responses (e.g., loss of clear zone) and the true case/control status we used Cohen's kappa. This provided us with a numerical summary between -1 and 1 for each sonologist, where 0 indicates no agreement beyond what is expected by chance, 1 indicates perfect agreement, and -1 indicates perfect disagreement.			

30